CA2260777C - Pentafluorobenzenesulfonamides and analogs - Google Patents

Pentafluorobenzenesulfonamides and analogs Download PDF

Info

Publication number
CA2260777C
CA2260777C CA002260777A CA2260777A CA2260777C CA 2260777 C CA2260777 C CA 2260777C CA 002260777 A CA002260777 A CA 002260777A CA 2260777 A CA2260777 A CA 2260777A CA 2260777 C CA2260777 C CA 2260777C
Authority
CA
Canada
Prior art keywords
pentafluorophenylsulfonamidobenzene
methoxy
hydroxy
pentafluorophenylsulfonamido
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002260777A
Other languages
French (fr)
Other versions
CA2260777A1 (en
Inventor
John Flygare
Julio Medina
Bei Shan
David Clark
Terry Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2260777A1 publication Critical patent/CA2260777A1/en
Application granted granted Critical
Publication of CA2260777C publication Critical patent/CA2260777C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
    • C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, vascular restenosis, microbial infections, and psoriasis, or as lead compounds for the development of such agents. The compositions include compounds of general formula (I).

Description

Pentafluorobenzenesulfonamides and Analogs INTRODUCTION
1~ield of the Invention The field of the invention is pentafluorobenzenesulfonamide derivatives and analogs and their use as pharmacologically active agents.
Backgro~d A number of human diseases stem from processes of uncontrolled or abnormal cellular proliferation. Most prevalent among these is cancer, a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body. A multitude of therapeutic agents have been developed over the past few decades for the treatment of various types of cancer. The most commonly used types of anticancer agents include: DNA-alkylating agents (e.g., cyclophosphamide, ifosfamide), antimetabolites (e.g., methotrexate, a folate antagonist, and S-fluorouracil, a pyrimidine antagonist), microtubule disruptors (e.g., vincristine, vinblastine, paclitaxel), DNA intercalators (e.g., doxorubicin, daunomycin, cisplatin), and hormone therapy (e.g., tamoxifen, futamide). The ideal antineoplastic drug would kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells.
It would also retain its efficacy against malignant cells even after prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess an ideal profile. Most possess very narrow therapeutic indexes, and in practically every instance cancerous cells exposed to slightly sublethal concentrations of a chemotherapeutic agent will develop resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents.
Psoriasis, a common chronic skin disease characterized by the presence of dry scales and plaques, is generally thought to be the result of abnormal cell proliferation.
The disease results from hyperproliferation of the epidermis and incomplete differentiation of keratinocytes.
Psoriasis often involves the scalp, elbows, knees, back, buttocks, nails, eyebrows, and genital SUBSTITUTE SHEET (RULE 26) regions, and may range in severity from mild to extremely debilitating, resulting in psoriatic arthritis, pustular psoriasis, and exfoliative psoriatic dermatitis. No therapeutic cure exists for psoriasis. Milder cases are often treated with topical corticosteroids, but more severe cases may be treated with antiproiiferative agents, such as the antimetabolite methotrexate, the DNA
synthesis inhibitor hydroxyurea, and the microtubule disrupter colchicine.
Other diseases associated with an abnormally high level of cellular proliferation include restenosis, where vascular smooth muscle cells are involved, inflammatory disease states, where endothelial cells. inflammatory cells and giomerular cells are involved, myocardial infarction, where heart muscle cells are involved, glomerular nephritis, where kidney cells are involved.
transplant rejection, where endothelial cells are involved, infectious diseases such as HIV
infection and malaria, where certain immune cells and/or other infected cells are involved, and the like. Infectious and parasitic agents per se (e.g. bacteria, trypanosomes, fungi, etc) are also subject to selective proliferative control using the subject compositions and compounds.
Accordingly, it is one object of the present invention to provide compounds which directly or indirectly are toxic to actively dividing cells and are useful in the treatment of cancer, viral and bacterial infections, vascular restenosis, inflammatory diseases, autoimmune diseases, and psoriasis.
A further object of the present invention is to provide therapeutic compositions for treating said conditions.
Still further objects are to provide methods for killing actively proliferating cells, such as cancerous, bacterial. or epithelial cells, and treating all types of cancers, infections, inflammatory, and generally proliferative conditions. A further object is to provide methods for treating other medical conditions characterized by the presence of rapidly proliferating cells, such as psoriasis and other skin disorders.
Other objects, features and advantages will become apparent to those skilled in the art from the following description and claims.
SUBSTITUTE SHEET (RULE 26) SUMMARY OF THE INVENTION
The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer. bacterial infections and psoriasis. or as lead compounds for the development of such agents.
In one embodiment, the invention provides for the pharmaceutical use of compounds of the general formula I and for pharmaceutically acceptable compositions of compounds of formula I:
F
F ~ Y- Z
F ~ F
F
or a physiologically acceptable salt thereof, wherein:
Y is -S(O)- or -S(O)2-;
Z is -NR~R2 or -OR3, where R~ and R2 are independently selected from hydrogen, substituted or unsubstituted (C 1-C 10)alkyl, substituted or unsubstituted (C 1-C 10)alkoxy, substituted or unsubstituted (C3-C6)alkenyl, substituted or unsubstituted (C2-C6)heteroalkyl, substituted or unsubstituted (C3-C6)heteroalkenyl, substituted or unsubstituted (C3-C6)alkynyl, substituted or unsubstituted (C3-C8)cycloalkyl, substituted or unsubstituted (CS-C7)cycloalkenyl, substituted or unsubstituted (CS-C7)cycloalkadienyl, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted aryl-(C3-C8)cycloalkyl, substituted or unsubstituted aryl-(CS-C7)cycloalkenyl, substituted or unsubstituted aryloxy-(C3-C8)cycloalkyl, SUBSTITUTE SHEET (RULE 26) substituted or unsubstituted aryl-(C1-C4)alkyl, substituted or unsubstituted aryl-(C1-C4)alkoxy, substituted or unsubstituted aryl-(C1-C4)heteroalkyl, substituted or unsubstituted aryl-(C3-C6)alkenyl, S substituted or unsubstituted aryloxy-(C1-C4)alkyl, substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroaryl-{C 1-C4)alkyl, substituted or unsubstituted heteroaryl-(C1-C4)alkoxy, substituted or unsubstituted heteroaryl-(C 1-C4)heteroalkyl, substituted or unsubstituted heteroaryl-(C3-C6)alkenyl, substituted or unsubstituted heteroaryloxy-{C1-C4)alkyl, and substituted or unsubstituted heteroaryloxy-(C2-C4)heteroalkyl, 1 S wherein R~ and R2 may be connected by a linking group E to give a substituent of the formula E

wherein E represents a bond, (C 1-C4) alkylene, or (C 1-C4) heteroalkylene, and the ring formed by R~, E, R2 and the nitrogen contains no more than 8 atoms. or preferably the R' and R2 may be covalently joined in a moiety that forms a 5- or 6-membered heterocyclic ring with the nitrogen atom of NR~RZ;
and where R3 is a substituted or unsubstituted aryl or heteroaryl group.
Substituents for the alkyl, alkoxy, alkenyl, heteroalkyl, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and cycloalkadienyl radicals are selected independently from -H
-OH
-O-(C 1-C 10}alkyl =O

SUBSTITUTE SHEET (RULE 26) -NH-(C 1-C 10)alkyl -N[(C 1-C 10)alkyl]2 -SH
-S-(C 1-C 10)alkyl 5 -halo -Si[(C1-C10)alkyl]3 in a number ranging from zero to (2N+1 ), where N is the total number of carbon atoms in such radical.
Substituents for the aryl and heteroaryl groups are selected independently from -halo -OH

-O-R' -O-C(O)-R' -NHZ

-NHR' -NR'R"

-SH

-SR' -R' -CN

-NO., -C02-R' -CONH~

-CONH-R' -CONR' R"

-O-C(O)-NH-R' -O-C(O)-NR' R"

-NH-C(O)-R' -NR"-C(O)-R' SUBSTITUTE SHEET (RULE 26) WO 98/05315 PCT/L1S97lI2720 -NH-C(O)-OR' -NR"-C(O)-R' -NH-C(NH2)=Nfl -NR'-C(NH2)=NH
-NH-C(NH2)=NR' -S(O)-R' -S(O)2-R.
-S(O)2-NH-R' -S(O)2-NR'R"

-CH(Ph)2 substituted or unsubstituted aryloxy substituted or unsubstituted arylamino substituted or unsubstituted heteroarylamino substituted or unsubstituted heteroaryloxy substituted or unsubstituted aryl-(C 1-C4)aikoxy, substituted or unsubstituted heteroaryl-(C1-C4)alkoxy, perfluoro(C1-C4)alkoxy, and perfluoro{C 1-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system:
and where R' and R" are independently selected from substituted or unsubstituted (C 1-C 10)alkyl, substituted or unsubstituted (C 1-C 10)heteroalkyl, substituted or unsubstituted (C2-C6)alkenyl, substituted or unsubstituted (C2-C6)heteroalkenyl, substituted or unsubstituted (C2-C6)alkynyl, substituted or unsubstituted (C3-C8)cycloalkyl, substituted or unsubstituted (C3-C8)heterocycloalkyl, substituted or unsubstituted (CS-C6)cycloalkenyl, substituted or unsubstituted {CS-Cb)cycloalkadienyl, SUBSTITUTE SHEET (RULE 26) WO 98105315 PCT/G'597112720 substituted or unsubstituted aryl, substituted or unsubstituted aryl-(C1-C4)alkyl, substituted or unsubstituted aryl-(C1-C4)heteroalkyl, substituted or unsubstituted aryl-(C2-C6)alkenyl, substituted or unsubstituted aryloxy-{C 1-C4)alkyl, substituted or unsubstituted aryloxy-(Cl-C4)heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaryl-(C1-C4)alkyl, substituted or unsubstituted heteroaryl-(C1-C4)heteroalkyl, substituted or unsubstituted heteroaryl-(C2-C6)alkenyl, substituted or unsubstituted heteroaryloxy-(C1-C4)alkyl, and substituted or unsubstituted heteroaryloxy-(C1-C4)heteroalkyl.
Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CH2)n-U-, wherein T and U are independently selected from N, O, and C, and n = 0-2. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)p-B-, wherein A and B are independently selected from C, O, N, S, SO, SO.,, and S02NR', and p = 1-3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CH2)q-X-(CH2)r , where q and r are independently 1-3, and X is selected from O, N, S, SO, SOZ and S02NR'. The substituent R' in SO,,NR' is selected from hydrogen or (C1-C6)alkyl.
In another embodiment, the invention provides novel methods for the use of pharmaceutical compositions containing compounds of the foregoing description of the general formula I. The invention provides novel methods for treating pathology such as cancer. bacterial infections and psoriasis, including administering to a patient an effective formulation of one or more of the subject compositions.
In another embodiment, the invention provides chemically-stable, pharmacologically active compounds of general formula I:
SUBSTITUTE SHEET (RULE 26) F
F / Y-Z
F ~ F I
F
or a pharmaceutically acceptable salt thereof, wherein:
Y is -S(O)- or -S(02)-; and Z is NR1R2, wherein R2 is an optionally substituted aryl or heteroaryl group, and R~ is selected from:
hydrogen, substituted or unsubstituted (C 1-C 10)alkyl, substituted or unsubstituted (C 1-C 10)alkoxy, substituted or unsubstituted (C3-Cb)alkenyl, substituted or unsubstituted (C2-C6)heteroalkyl, substituted or unsubstituted (C3-C6)heteroalkenyl, substituted or unsubstituted (C3-C6)alkynyl, substituted or unsubstituted (C3-C8)cycloalkyl, substituted or unsubstituted (CS-C7)cycloalkenyl, substituted or unsubstituted (CS-C7)cycloalkadienyl, substituted or unsubstituted aryl, substituted or unsubstituted aryloxy, substituted or unsubstituted aryl-(C3-C8)cycloalkyl, substituted or unsubstituted aryl-(CS-C7)cycloalkenyl, substituted or unsubstituted aryloxy-{C3-C8)cycloalkyl, substituted or unsubstituted aryl-(C 1-C4)alkyl, substituted or unsubstituted aryl-(C 1-C4)alkoxy, substituted or unsubstituted aryl-(C1-C4)heteroalkyl, substituted or unsubstituted aryl-(C3-C6)alkenyl, substituted or unsubstituted aryloxy-(C 1-C4)alkyl, substituted or unsubstituted aryloxy-(C2-C4)heteroalkyl, substituted or unsubstituted heteroaryl, SUBSTITUTE SHEET (RULE 26) substituted or unsubstituted heteroaryloxy, substituted or unsubstituted heteroaryl-(C1-C4)alkyi, substituted or unsubstituted heteroaryl-(C1-C4)alkoxy, substituted or unsubstituted heteroaryl-(CI-C4)heteroalkyl, substituted or unsubstituted heteroaryl-(C3-C6)alkenyl, substituted or unsubstituted heteroaryloxy-(C1-C4)alkyl, and substituted or unsubstituted heteroaryloxy-(C2-C4)heteroalkyl, wherein R~ and R2 may be connected by a linking group E to give a substituent of the formula E

wherein E represents a bond, (C1-C4) alkylene, or (CI-C4) heteroalkylene, and the ring formed by R~, E, R2 and the nitrogen contains no more than 8 atoms, or preferably the R~ and R2 may be covalently joined in a moiety that forms a 5- or b-membered heterocyclic ring with the nitrogen atom of NR~R2;
provided that:
in the case that Y is -S(02)-, and R' is hydrogen or methyl, then R2 is substituted phenyl or heteroaryl group;
in the case that Y is -S(O~)- and R2 is a ring system chosen from 1-naphthyl.
5-quinolyl, or 4-pyridyl, then either R~ is not hydrogen or R2 is substituted by at least one substituent that is not hydrogen;
in the case that Y is -S(02}-, RZ is phenyl, and R~ is a propylene unit attaching the nitrogen of -NR~R2- to the 2- position of the phenyl ring in relation to the sulfonamido group to form a 1,2,3,4-tetrahydroquinoline system, one or more of the remaining valences on the bicyclic system so formed is substituted with at least one substituent that is not hydrogen;
in the case that Y is -S(02)- and R2 is phenyl substituted with 3-(1-hydroxyethyl), 3- .dimethylamino, 4-dimethylamino, 4-phenyl, 3-hydroxy, 3-hydroxy-4-diethylaminomethyl, 3,4-methylenedioxy, 3,4-ethylenedioxy, 2-(I-pyrrolyl}, or 2-methoxy-4-(1-morpholino), then either Ri is not hydrogen or when RI is hydrogen, one or more of the remaining valences on the phenyl ring of R2 is substituted with a substituent that is not hydrogen;
in the case that Y is -S(Oz)- and R' is 2-methylbenzothiazol-5-yl, SUBSTITUTE SHEET (RULE 26) WO 98/05315 1 ~ PCT/US97/12720 6-hydroxy-4-methyl-pyrimidin-2-yl, 3-carbomethoxypyrazin-2-yl, -5-carbomethoxypyrazin-2-yl, 4-carboethoxy-1-phenylpyrazol-5-yl, 3-methylpyrazol-5-yl, 4-chloro-2-methylthiopyrimidin-6-yl, 2-trifluoromethyl-1,3,4-thiadiazol-5-yl, 5,6,7,8-tetrahydro-2-naphthyl, 4-methylthiazol-2-yl, 6,7-dihydroindan-5-yl, 7-chloro-5-methyl-1,8-naphthyridin-2-yl, 5,7-dimethyl-1,8-naphthyridin-2-yl, or 3-cyanopyrazol-4-yl, R1 is a group other than hydrogen.
DETAILED DESCRIPTION OF THE INVENTION
The term "alkyl" by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon radical, including dl- and mufti-radicals, having the number of carbon atoms designated (i.e. C1-C10 means one to ten carbons) and includes straight or branched chain groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, homologs and isomers of n-pentyl, n-hexyl, 2-methylpentyl, 1,5-dimethylhexyl, 1-methyl-4-isopropylhexyl and the like. The term "alkylene"
by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified by -CH2CH,,CH.,CH,,-. A "lower alkyl" is a shorter chain alkyl, generally having six or fewer carbon atoms.
The term "heteroalkyl" by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain radical consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S. and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s} may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the fragment to which it is attached. as well as attached to the most distal carbon atom in the heteroalkyl group.
Examples include -O-CH,,-CHI-CH3, -CH,,-CH,,-O-CH3, -CH,,-CH,,-CH.,-OH, -CH2-CH2-NH-CH3, -CH,,-CH2-N(CH3}-CH3, -CH,,-S-CH,,-CH3, -CH,,-CH,,-S(O)-CH3, -O-CH.,-CH2-CH2-NH-CH3, and -CH.,-CH,,-S(O),,-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3. The term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified by -CHZ-CH,,-S-CH.,-CH2- and -CH,,-S-CH.,-CH2-NH-.
The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with SUBSTITUTE SHEET (RULE 26) other terms, represent, unless otherwise stated, cyclic versions of "alkyl"
and "heteroalkyl", respectively. Examples of cycloalkyl include cyclopentyl, cyclohexyl, cycloheptyl, and the like.
Examples of heterocycloalkyl include 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
The term "alkenyl" employed alone or in combination with other terms, means, unless otherwise stated, a stable straight chain or branched monounsaturated or diunsaturated hydrocarbon group having the stated number of carbon atoms. Examples include vinyl, propenyl (allyl), crotyl, isopentenyl, butadienyl, 1,3-pentadienyl, 1,4-pentadienyl, and the higher homologs and isomers. A divalent radical derived from an alkene is exemplified by -CH=CH-CHZ-.
The term ''heteroalkenyl" by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain monounsaturated or diunsaturated hydrocarbon radical consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quarternized. Up to two heteroatoms may be placed consecutively. Examples include -CH=CH-O-CH3, -CH=CH-CH,,-OH, -CHZ-CH=N-OCH3, -CH=CH-N(CH3)-CH3, and -CHZ-CH=CH-CH,,-SH.
The term "alkynyl" employed alone or in combination with other terms, means, unless otherwise stated, a stable straight chain or branched hydrocarbon group having the stated number of carbon atoms, and containing one or two carbon-carbon triple bonds, such as ethynyl, 1- and 3-propynyl, 4-but-1-ynyl, and the higher homologs and isomers.
The term "alkoxy'' employed alone or in combination with other terms, means, unless otherwise stated, an alkyl group, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy and the higher homologs and isomers.
The terms "halo" or "halogen" by themselves or as part of another substituent mean, unless otherwise stated. a fluorine, chlorine, bromine, or iodine atom.
The term ''aryl" employed alone or in combination with other terms, means, unless otherwise stated, a phenyl, 1-naphthyl, or 2-naphthyl group. The maximal number of substituents allowed on each one of these ring systems is five, seven, and seven, respectively.
SUBSTITUTE SHEET (RULE 26) Substituents are selected from the group of acceptable substituents listed above.
The term "heteroaryl" by itself or as part of another substituent means, unless otherwise stated, an unsubstituted or substituted, stable, mono- or bicyclic heterocyclic aromatic ring system which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S. and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen atom may optionally be quaternized. The heterocyclic system may be attached, unless otherwise stated at any heteroatom or carbon atom which affords a stable structure. The heterocyclic system may be substituted or unsubstituted with one to four substituents independently selected from the list of acceptable aromatic substituents listed above. Examples of such heterocycles include 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyi, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-1 S quinolyl, and 6-quinolyl.
Pharmaceutically acceptable salts of the compounds of Formula I include salts of these compounds with relatively nontoxic acids or bases, depending on the particular substituents found on specific compounds of Formula I. When compounds of Formula I contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of compound I with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of Formula I
contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of compound I with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, oxalic, malefic, malonic, benzoic, succinic, suberic, fiunaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as SUBSTITUTE SHEET (RULE 26) arginate and the like, and salts of organic acids like gluconic or galactunoric acids and the like (see, for example, Berge, S.M., et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science. Vol.
66, pages 1-19 (1977)). Certain specific compounds of Formula I contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
The free base form may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
Certain compounds of the present invention possess asymmetric carbon atoms (optical centers); the racemates, diastereomers, and individual isomers are all intended to be encompassed within the scope of the present invention.
The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H) or carbon-14 (14C). All isotopic variations of the compounds of the present invention. whether radioactive or not, are intended to be encompassed within the scope of the present invention.
In various preferred embodiments of the pharmaceutical compositions of compounds of formula I, Y is S(02) and Z is NR1R2, wherein R~ is hydrogen or methyl, and RZ
is a substituted phenyl, preferably mono-, dl-, or trisubstituted as follows. In one group of preferred compounds, Y is S(02) and Z is NR1R2, wherein R' is hydrogen or methyl, and R' is a phenyl group, preferably substituted in the para position by one of the following groups: hydroxy, amino, (C 1-C 10)alkoxy, (C 1-C 10)alkyl, (C 1-C 10)alkylamino. and [di(C 1-C
10)alkyl]amino. with up to four additional substituents independently chosen from hydrogen, halogen, (C1-C10)alkoxy, (C1-C10)alkyl, and [di(C1-C10)alkyl]amino. Also preferred are compounds of formula I where there is no linking group E between R1 and R2.
Illustrative examples of pharmaceutical compositions and compounds of the subject pharmaceutical methods include:
SUBSTITUTE SHEET (RULE 26) 2-Fluoro-1-methoxy-4-pentafluorophenylsulfinamidobenzene;
4-Dimethylamino-1-pentafluorophenylsulfinamidobenzene;
4-Methyl-6-methoxy-2-pentafluorophenylsulfonamidopyrimidine;
4,6-Dimethoxy-2-pentafluorophenylsulfonamidopyrimidine;
2-Pentafluorophenylsulfonamidothiophene;
3-Pentafluorophenylsulfonamidothiophene;
3-Pentafluorophenylsulfonamidopyridine;
4-Pentafluorophenylsulfonamidopyridine;
4-{N, N,-Dimethylamino)-1-(N-ethylpentafluorophenylsulfonamido)-benzene;
4-tert-Butoxy-1-pentafluorophenylsulfonamidobenzene;
3-tert-Butoxy-1-pentafluorophenyisulfonamidobenzene;
2-tert-Butoxy-1-pentafluorophenylsulfonamidobenzene;
4-Isopropoxy-1-pentafluorophenylsulfonamidobenzene;
3-Isopropoxy-1-pentafluorophenylsulfonamidobenzene;
2-Isopropoxy-1-pentafluorophenylsulfonamidobenzene;
2-Methoxy-1,3-difluoro-5-pentafluorophenylsulfonamidobenzene;
4-Cyclopropoxy-1-pentafluorophenylsulfonamidobenzene;
3-Fluoro-4-cyclopropoxy-1-pentafluorophenylsulfonamidobenzene;
3-Hydroxy-4-cyclopropoxy-1-pentafluorophenylsulfonamidobenzene;
1-Hydroxy-2,3-methylenedioxy-5-pentafluorophenylsulfonamidobenzene;
1-Hydroxy-2,3-ethylenedioxy-~-pentafluorophenylsulfonamidobenzene;
1-Hydroxy-2,3-carbodioxy-5-pentafluorophenylsulfonamidobenzene;
1,3-Dihydroxy-2-ethoxy-5-pentafluorophenylsulfonamidobenzene;
1-Pentafluorophenylsulfonylindole;
1-Pentafluorophenylsulfonyl(2,3-dihydro)indole;
1-Pentafluorophenylsulfonyl( 1,2-dihydro)quinoline;
1-Pentafluorophenylsulfonyl( 1,2,3,4-tetrahydro)quinoline;
3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene;
4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene;
2-Chloro-~-pentafluorophenylsulfonamidopyridine;
2-Hydroxy-1-methoxy-4-[N-5-hydroxypent-1-yl)pentafluorophenyl-sulfonamidoJbenzene;
SUBSTITUTE SHEET (RULE 26) 4-( 1, I -Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene;
1-Bromo-3-hydroxy-4-methoxy- I -pentafluorophenylsulfonamidobenzene;
2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene;
I -Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene;
5 3-Chloro-I-pentafluorophenylsulfonamidobenzene;
4-Chloro- I -pentafluorophenylsulfonamidobenzene;
3-Nitro-1-pentafluorophenylsulfonamidobenzene;
4-Methoxy-1-pentafluorophenylsulfonamido-3-(trifluoromethyi)benzene;
4-Methoxy- I -[N-(2-propeny 1)pentafluorophenylsulfonamido]benzene;
10 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene;
4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene;
1-[N-(2,3-Dihydroxypropyl )pentafluorophenylsulfonamido]-4-methoxy-benzene;
I -(N-(3,4-Dihydroxybutyl}pentafluorophenylsulfonamido)-4-methoxybenzene;
1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene;
15 1-(N-{4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene;
4-Methoxy- I -(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)-benzene;
3-Amino-4-methoxy-I-pentafluorophenylsulfonamidobenzene;
4-Butoxy-I-pentafluorophenylsulfonamidobenzene;
1-Pentafluorophenylsulfonamido-4-phenoxybenzene;
6-Pentafluorophenylsulfonamidoquinoline;
2,3-Dihydro-~-pentafluorophenylsulfonamidoindole;
S-Pentafluorophenylsulfonamidobenzo[a]thiophene;
5-Pentafluorophenylsulfonamidobenzo[a]furan;
3-Hydroxy-4-( I -propenyl)-1-pentafluorophenylsulfonamidobenzene;
4-Benzyloxy-I-pentafluorophenylsulfonamidobenzene;
4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene;
2-Methoxy- I -pentafluorophenylsulfonamidobenzene;
4-Allyloxy-1-pentafluorophenyisulfonamidobenzene;
I-Pentafluorophenylsulfonamido-4-propoxybenzene;
4-(i-Methyl)ethoxy-I-pentafluorophenylsulfonamidobenzene;
1.2-Methylenedioxy-4-pentafluorophenylsulfonamidobenzene;
SUBSTITUTE SHEET (RULE 26) 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene;
4-(N,N Diethylamino)-1-pentafluorophenylsulfonamidobenzene;
4-Amino- I -pentafluorophenylsulfonamidobenzene;
Pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamidoindazole;
4-(N, N Dimethylamino)-1-(N methylpentafluorophenylsulfonamido)-benzene:
1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene;
3,5-Dimethoxy- I -pentafluorophenylsulfonamidobenzene;
3-Ethoxy-1-pentafluorophenylsulfonamidobenzene;
7-Hydroxy-2-pentafluorophenylsulfonamidonaphthalene;
3-Phenoxy-1-pentafluorophenylsulfonamidobenzene;
4-( 1-Morpholino)- I -pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene;
2-Hydroxy-1,3-methoxy-~-pentafluorophenylsulfonamidobenzene;
1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene;
3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene;
3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene;
2-Fluoro- I -methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene:
4-(N,N Dimethylamino)-I-pentafluorophenylsulfonamidobenzene, hydrochloride;
2-Methoxy-S-pentafluorophenylsulfonamidopyridine; and 2-Anilino-3-pentafluorophenylsulfonamidopyridine.
Examples of the most preferred pharmaceutical compositions and compounds of the subject pharmaceutical methods include:
4-(N,N Dimethylamino)-1-pentafluorophenylsulfonamidobenzene;
3-(N,N Dimethylamino)-1-pentafluorophenylsulfonamidobenzene;
I,2-Ethylenedioxy-4-pentafluorophenylsulfonamidobenzene;
2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Fluoro-I-methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Hydroxy-I-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt;
2-Hydroxy- I -methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt;
SUBSTITUTE SHEET (RULE 26) 2-Fluoro-I-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt;
2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt;
4-Methoxy- I -pentafluorophenylsulfonamidobenzene;
3-Hydroxy- I -pentafluorophenylsulfonamidobenzene;
4-Hydroxy-1-pentafluorophenylsulfonamidobenzene;
1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamidoindole;
4-Ethoxy-1-pentafluorophenylsulfonamidobenzene;
3-Methoxy-1-pentafluorophenylsulfonamidobenzene;
I 0 2-Bromo- I -methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Chloro- I -methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene;
2-Bromo-4-methoxy-~-hydroxy- I -pentafluorophenylsulfonamidobenzene;
I-Bromo-4-fluoro-~-methoxy-2-pentafluorophenylsulfonamidobenzene;
4-Chloro-1-pentafluorophenylsulfonamidobenzene; and 3-Amino-4-methoxy- I -pentafluorophenylsulfonamidobenzene.
The invention provides for certain novel compounds of general Formula I that possess one or more valuable biological activities such as a pharmacologic, toxicologic, metabolic, etc.
Exemplary compounds of this embodiment of the invention include:
2-Fluoro-1-methoxy-4-pentafluorophenylsulfinamidobenzene;
4-Dimethylamino-1-pentafluorophenylsulfinamidobenzene;
4-Methyl-6-methoxy-2-pentafluorophenylsulfonamidopyrimidine;
4,6-Dimethoxy-2-pentafluorophenylsulfonamidopyrimidine;
2-Pentafluorophenylsulfonamidothiophene;
3-Pentafluorophenylsulfonamidothiophene;
3-Pentafluorophenylsulfonamidopyridine;
4- .Pentafluorophenylsulfonamidopyridine;
4-(N,N,-Dimethylamino)-1-(N-ethylpentafluorophenylsulfonamido) benzene;
4-tert-Butoxy- I -pentafluorophenylsulfonamidobenzene;
3-tert-Butoxy-I-pentafluorophenylsulfonamidobenzene;
2-tert-Butoxy-1-pentafluorophenylsulfonamidobenzene;
SUBSTITUTE SHEET (RULE 26) 4-Isopropoxy-1-pentafluorophenylsulfonamidobenzene;
3-Isopropoxy-1-pentafluorophenylsulfonamidobenzene;
2-Isopropoxy-1-pentafluorophenylsulfonamidobenzene;
2-Methoxy-1,3-difluoro-~-pentafluorophenylsulfonamidobenzene;
1-Hydroxy-2,3-methylenedioxy-~-pentafluorophenylsulfonamidobenzene;
1-Hydroxy-2,3-ethylenedioxy-5-pentafluorophenylsulfonamidobenzene;
1-Hydroxy-2,3-carbodioxy-5-pentafluorophenylsulfonamidobenzene;
1,3-Dihydroxy-2-ethoxy-5-pentafluorophenylsulfonamidobenzene;
1-Pentafluorophenylsulfonylindole;
1-Pentafluorophenylsulfonyl(2,3-dihydro)indole;
1-Pentafluorophenylsulfony I( 1,2-dihydro)quinoline;
1-Pentafluoropheny lsulfonyl( 1,2,3,4-tetrahydro)quinoline;
3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene;
4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene;
2-Chloro-5-pentafluorophenylsulfonamidopyridine;
2-Hydroxy-1-methoxy-4-[N-5-hydroxypent-1-yl)pentafluorophenyl-sulfonamido]benzene;
4-( 1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene;
1-Bromo-3-hydroxy-4-methoxy- I -pentafluorophenylsulfonamidobenzene;
2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene;
1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene;
3-Chloro-1-pentafluorophenylsulfonamidobenzene;
4-Chloro-1-pentafluorophenylsulfonamidobenzene;
3-Nitro-1-pentafluorophenylsulfonamidobenzene;
4-Methoxy-1-pentafluorophenylsulfonamido-3-{trifluoromethyl)benzene;
4-Methoxy-1-[N-(2-propenyl)pentafluorophenylsulfonamido]benzene;
1-{N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene;
4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene;
1-[N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido]-4-methoxy-benzene;
1-(N-(3,4-Dihydroxybutyl)pentafluorophenyisulfonamido)-4-methoxybenzene;
1-(N-{4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene;
1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene;
SUBSTITUTE SHEET (RULE 26) 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluoraphenylsulfonamido)-benzene;
3 -Amino-4-methoxy-1-pentafluoropheny lsulfonamidobenzene;
4-Butoxy-1-pentafluorophenylsulfonamidobenzene;
I-Pentafluorophenylsulfonamido-4-phenoxybenzene;
4-Benzyloxy-I-pentafluorophenylsulfonamidobenzene;
4-Methylmercapto- I -pentafluorophenylsulfonamidobenzene;
2-Methoxy-1-pentafluorophenylsulfonamidobenzene;
4-Allyloxy- I -pentafluorophenylsulfonamidobenzene;
I-Pentafluorophenylsulfonamido-4-propoxybenzene;
4-( 1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene;
1,2-Methylenedioxy-4-pentafluorophenylsulfonamidobenzene;
1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene;
4-(N, N-Diethylamino)- l -pentafluorophenylsulfonamidobenzene;
4-Amino-1-pentafluorophenylsulfonamidobenzene;
1 S Pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamidoindazole;
4-(N, N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)-benzene;
1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene;
3,5-Dimethoxy- I -pentafluorophenylsulfonamidobenzene;
3-Ethoxy-1-pentafluorophenylsulfonamidobenzene;
7-Hydroxy-2-pentafluorophenylsulfonamidonaphthalene;
3-Phenoxy- I -pentafluorophenylsulfonamidobenzene;
4-( I -Morpholino)-1-pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene;
2-Hydroxy-1.3-methoxy-~-pentafluorophenylsulfonamidobenzene;
1,2-Dihydroxy-3-methoxy-~-pentafluorophenylsulfonamidobenzene;
S-Pentafluorophenylsulfonamido-1,2.3-trihydroxybenzene;
4-Cyclopropoxy-1-pentafluorophenylsulfonamidobenzene;
3-Fluoro-4-cyclopropoxy-1-pentafluorophenylsuifonamidobenzene;
6-Pentafluorophenylsulfonamidoquinoline;
2,3-Dihydro-~-pentafluorophenylsulfonamidoindole;
SUBSTITUTE SHEET (RULE 26) 5-Pentafluorophenylsulfonamidobenzo[a]thiophene;
S-Pentafluorophenylsulfonamidobenzo[aJfuran;
3-Hydroxy-4-( 1-propenyl)-1-pentafluorophenylsulfonamidobenzene;
3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene;
5 3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene;
2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene;
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, hydrochloride;
and, 2-Analino-3-pentafluorophenylsulfonamidopyridine.
Preferred compounds of this embodiment of the invention have specific 10 pharmacological properties. Examples of the most preferred compounds of this embodiment of the invention include:
4-(N,N Dimethylamino)-1-pentafluorophenylsulfonamidobenzene;
3-(N,N Dimethylamino)-1-pentafluorophenylsulfonamidobenzene;
1,2-Ethylenedioxy-4-pentafluorophenylsulfonamidobenzene;
15 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt;
2-Hydroxy-1-methoxy-4-pentafluorophenyisulfonamidobenzene, potassium salt;
2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt;
20 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt;
4-Methoxy-1-pentafluorophenylsulfonamidobenzene;
3-Hydroxy-1-pentafluorophenylsulfonamidobenzene;
4-Hydroxy-1-pentafluorophenylsulfonamidobenzene;
1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene;
5-Pentafluorophenylsulfonamidoindole;
4-Ethoxy-1-pentafluorophenylsulfonamidobenzene;
3-Methoxy-1-pentafluorophenylsulfonamidobenzene;
2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene;
2-Chloro-1-methoxy-4-pentafluoropheny lsul fonamidobenzene;
2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene;
2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene;
SUBSTITUTE SHEET (RULE 26) 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene;
4-Chloro-1-pentafluorophenylsulfonamidobenzene; and, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
In alternative aspects, the invention provides for the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat or prevent a disease state, or to formulate a medicament to treat or prevent a disease state, wherein the disease state is characterized by an abnormal or undesired level of cell proliferation. The invention also provides methods of inhibiting the growth of a target cell in vitro, comprising contacting said cell with an effective amount of a compound of formula I, or a salt thereof. The invention further provides methods for the preparation of a pharmaceutical composition for the treatment of a disease state characterized by an abnormal or undesired level of cell proliferation comprising formulating a pharmaceutically acceptable diluent or carrier with a compound of formula I, or a pharmaceutically acceptable salt thereof. The invention also provides commercial packages 1 S containing, as active pharmaceutical ingredient, a compound of formula I, or a pharmaceutically acceptable salt thereof, together with instructions for use of the compound for the treatment or prevention of a disease state characterized by an abnormal or undesired level of cell proliferation.
In some embodiments, in formula I: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R' is selected from hydrogen, substituted or unsubstituted (C 1-C 10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and RZ is substituted or unsubstituted aryl. Alternatively, R1 may be hydrogen or lower alkyl, and RZ
is optionally substituted phenyl. In further alternatives, R1 may be hydrogen or methyl, and the substituents on RZ are independently selected from lower alkyl, hydroxy, lower alkoxy, amino, amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen. Further alternative embodiments of the compounds for use in the alternative aspects of the invention are specifically identified by name elsewhere herein.

21a In selected embodiments, the invention provides for the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat or prevent a disease state, or , to formulate a medicament to treat or prevent a disease state, characterized by an abnormal or undesired level of cell proliferation:
Y-Z
wherein: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R' is selected from hydrogen, substituted or unsubstituted (C 1-C 10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and Rz is substituted or unsubstituted aryl. Alternatively, R' may be hydrogen or lower alkyl, and RZ
is optionally substituted phenyl. R1 may be hydrogen or methyl, and the substituents on RZ
are independently selected from lower alkyl, hydroxy, lower alkoxy, amino, amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen. The compound is selected from the group consisting of 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Diethylamino)-1-pentafluorophenylsulfonamidobenzene, 4-Amino-1-pentafluorophenylsulfonamidobenzene, Pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 21b 4-(N,N-Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene, 1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Phenoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4( 1-Morpholino)-1-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene, 2-Hydroxy-1,3-dimethoxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene, 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene hydrochloride, 3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene, 4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-[N-(5-hydroxypentyl)pentafluorophenylsulfonamido]-benzene, 4-( l,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenyisulfonamidobenzene; potassium salt, 21c 3-Chloro-1-pentafluorophenylsulfonamidobenzene, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, 3-Nitro-1-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamido-3-trifluoromethylbenzene, 4-Methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)benzene, 4-Methoxy-3-nitro-1-pentafluorophenylsulfonamidobenzene, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Butoxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-phenoxybenzene, 4-Benzyloxy-1-pentafluorophenylsulfonamidobenzene, 4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene, 2-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Allyloxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-propoxybenzene, 4-(1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, and 4-tent-Butoxy-1-pentafluorophenylsulfonamidobenzene.
Alternatively, the compound may be selected from the group consisting o~
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-I-pentafluorosulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 21d 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, and 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
Alternatively, the compound may be selected from the group consisting of 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, and 2-Hydroxy-1-methoxy-pentafluorophenylsulfonamidobenzene; monopotassium salt. The compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene. The compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt. The compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt.
Alternatively, the use of the foregoing compounds of formula I may be to contact a target cell to inhibit the growth of the target cell, or where the proliferative disease state is cancer or a cancerous condition.
The compounds of the invention may be formulated for oral administration, or formulated for intravenous administration, or formulated for intramuscular administration.
The use of the compound according to the invention may be in combination with the use of an antineoproliferative, chemotherapeutic, or cytotoxic agent that is not represented by formula I.

21e The use of the compound according to the invention may be such that the compound is conjugated to a targeting molecule which preferentially directs the compound to a targeted cell.
The use of the compounds of the invention may be such that, wherein Rl is hydrogen or methyl, and RZ is substituted phenyl wherein the substituents on R2, ranging in number from one to four are independently chosen from lower alkyl, lower alkoxy, amino optionally substituted with one or two lower alkyls, arylamino, heteroarylamino, phenoxy, and halogen.
In an alternative aspect, the invention provides a method of inhibiting the growth of a target cell in vitro, comprising contacting said cell with an effective amount of a compound of formula I, or a salt thereof:
wherein: Y is -S(O)- or -S(O)Z-; Z is -NR~R2; where R' is selected from hydrogen, substituted or unsubstituted (CI-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and RZ is substituted or unsubstituted aryl.
In an alternative aspect, the invention provides a method for the preparation of a pharmaceutical composition for the treatment of a disease state characterized by an abnormal or undesired level of cell proliferation comprising formulating a pharmaceutically acceptable diluent or carrier with a compound of formula I, or a pharmaceutically acceptable salt thereof:

21f Y-Z
wherein: Y is -S(O)- or -S(O)2-; Z is -NR~R2; where R' is selected from hydrogen, substituted or unsubstituted (Cl-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and RZ is substituted or unsubstituted aryl.
In the foregoing methods, R~ may for example be hydrogen or lower alkyl, and RZ is optionally substituted phenyl. Alternatively, R' may be hydrogen or methyl, and the substituents on RZ are independently selected from lower alkyl, hydroxy, lower alkoxy, amino, amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen.
In the foregoing methods, the compound may for example be selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Diethylamino)-1-pentafluorophenylsulfonamidobenzene, 4-Amino-1-pentafluorophenylsulfonamidobenzene, Pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-(N,N-Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene, 1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene, 21g 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Phenoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4( 1-Morpholino)-1-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene, 2-Hydroxy-1,3-dimethoxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene, 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene hydrochloride, 3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene, 4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-[N-(5-hydroxypentyl)pentafluorophenylsulfonamido]-benzene, 4-( 1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenyisulfonamidobenzene; potassium salt, 3-Chloro-1-pentafluorophenylsulfonamidobenzene, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, 21h 3-Nitro-1-pentafluorophenylsulfonamidobenzene, 4-Methoxy-I-pentafluorophenylsulfonamido-3-trifluoromethylbenzene, 4-Methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)benzene, 4-Methoxy-3-nitro-1-pentafluorophenylsulfonamidobenzene, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Butoxy-I-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-phenoxybenzene, 4-Benzyloxy-1-pentafluorophenylsulfonamidobenzene, 4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene, 2-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Allyloxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-propoxybenzene, 4-(1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, and 4-tent-Butoxy-1-pentafluorophenylsulfonamidobenzene.
Alternatively, in the foregoing methods, the compound may for example be selected from the group consisting o~
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-I-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorosulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 21i 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, and 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
In the foregoing methods, the compound may for example be selected from the group consisting of 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, and Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt.
Alternatively, the compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene. Alternatively, the compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt. Alternatively, the compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt.
In an alternative embodiment, the invention provides a commercial package containing, as active pharmaceutical ingredient, a compound of formula I, or a pharmaceutically acceptable salt thereof, together with instructions for use of the compound for the treatment or prevention of a disease state characterized by an abnormal or undesired level of cell proliferation:

21j Z
wherein: Y is -S(O)- or -S(O)Z-; Z is -NR~RZ; where R' is selected from hydrogen, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and RZ is substituted or unsubstituted aryl.
S In the commercial package of the invention, Rl may be hydrogen or lower alkyl, and RZ is optionally substituted phenyl. Alternatively, R' may be hydrogen or methyl, and the substituents on RZ are independently selected from lower alkyl, hydroxy, lower alkoxy, amino, amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen. Alternatively, the compound is selected from the group consisting of 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Diethylamino)-1-pentafluorophenylsulfonamidobenzene, 4-Amino-I-pentafluorophenylsulfonamidobenzene, Pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-(N,N-Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene, 1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene, 21k 3-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Phenoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4( 1-Morpholino)-1-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene, 2-Hydroxy-1,3-dimethoxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene, 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dihydroxy-I-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene hydrochloride, 3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene, 4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-I-methoxy-4-[N-(5-hydroxypentyl)pentafluorophenylsulfonamido]-benzene, 4-( 1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-I-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenyisulfonamidobenzene; potassium salt, 3-Chloro-1-pentafluorophenylsulfonamidobenzene, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, 3-Nitro-1-pentafluorophenylsulfonamidobenzene, 4-Methoxy-I-pentafluorophenylsulfonamido-3-trifluoromethylbenzene, 4-Methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)benzene, 4-Methoxy-3-nitro-1-pentafluorophenylsulfonamidobenzene, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Butoxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-phenoxybenzene, 4-Benzyloxy-1-pentafluorophenylsulfonamidobenzene, 4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene, 2-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Allyloxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-propoxybenzene, 4-(1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, and 4-tent-Butoxy-1-pentafluorophenylsulfonamidobenzene.
In the commercial package, the compound may be selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorosulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 21m 2-Bromo-I-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, IO 4-Chloro-1-pentafluorophenylsulfonamidobenzene, and 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
In the commercial package, the compound may be selected from the group consisting of 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, and 2-Hydroxy-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt.
Alternatively, the compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene.
Alternatively, the compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt. Alternatively, the compound may be 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt.

SYNTHESIS
Scheme I
Syntheses of pentafluorophenylsulfonamides, sulfonic esters, sulfinamides, and sulfinic esters F F F
O
F / ~ ~ ~ --.-~ F / ~ ~~ -R2 1 CI HNR~R2 Il F F F F O
Sulfonamide F F
°_ 2 F / \ S~ HOR3 ~ F / ~ 'SO'.-O _Rs CI O
F F F F
Sulfonic ester F F O F F
Ii F / ~ S-CI "~ F / ~ _~-N-R2 HNR~RZ
F F F F R~
Sulfinamide F F F F

F / ~ S-CI ---~ F / ~ S-OR3 HORS
F F F F
Sulfinic ester SUBSTITUTE SHEET (RULE 26) Scheme II
Alternative synthesis of N,N-disubstituted pentafluorophenylsulfonamides.
F F F
o O
..
/ ~ o- ~... R i ---~,. F / ~ I j - If f- R ~
F - H ER F .-F O R2 F
Scheme III
Syntheses of phenols F F O F F
/ ~
F _ S-N-Ar(OMe)X F S-N-Ar(OH)x .. O R i F F O R1 BBr ~ F F
x=1-3 SUBSTITUTE SHEET (RULE 26) The invention provides methods of making the subject compounds and compositions.
In one general embodiment, the methods involve combining pentafluorophenylsulfonyl chloride with an amine having the general formula RiR2NH under conditions whereby the pentafluorophenylsulfonyl chloride and amine react to form the desired compound, and isolating the compound.
Compounds with the generic structure 1 or 3 {Scheme I) may be prepared by reacting the appropriate starting amine in a solvent such as tetrahydrofuran (THF), dimethylformamide (DMF), ether, toluene or benzene in the presence of a base such as pyridine, p-dimethylaminopyridine, triethylamine, sodium carbonate or potassium carbonate and pentafluorophenylsulfonyl chloride or pentafluorophenylsulfinyl chloride, respectively.
Pyridine itself may also be used as the solvent. Preferred solvents are pyridine and DMF
and preferred bases are pyridine, triethylamine, and potassium carbonate. This reaction can be carried out at a temperature range of 0 °C to 100 °C, conveniently at ambient temperature.
Compounds of the generic structure 1 can also be obtained by treating the starting sulfonamide (Scheme II) with a base such as LDA, NaH, dimsyl salt, alkyl lithium, potassium carbonate, under an inert atmosphere such as argon or nitrogen, in a solvent such as benzene, toluene, DMF or THF with an alkylating group containing a leaving group such a Cl, Br, I, Ms0-, Ts0-, TFAO-, represented by E in Scheme II. A preferred solvent for this reaction is THF and the preferred base is lithium bis(trimethylsilyl)amide.
This reaction can be carned out at a temperature range of 0 °C to 100 °C, conveniently at ambient temperature.
Sulfonic esters (2) and sulfinic esters (4) may be prepared by reacting the appropriate starting phenol in a solvent such as THF, DMF, toluene or benzene in the presence of a base such as pyridine, triethylamine, sodium carbonate, potassium carbonate or 4-dimethylaminopyridine with pentafluorophenylsulfonyl chloride or pentafluorophenylsulfinyl chloride, respectively. Pyridine itself may also be used as the solvent. Preferred solvents are pyridine and DMF and preferred bases are sodium carbonate and potassium carbonate. This reaction can be carried out at a temperature range of 0 °C to 100 °C, conveniently at ambient temperature.
~0 Compounds of the general structure 5, in which Ar is an aromatic group and x is from one to three, can be obtained from the corresponding methyl ethers (Scheme III) by reaction SUBSTITUTE SHEET (RULE 26) with boron tribromide in a solvent of low polarity such as hexanes or CH.,C12 under an inert atmosphere at a temperature ranging from -45~ to 30 °C. In a preferred embodiment. the reaction is carried out in CH.,CI., at about 30 °C.
Occasionally, the substrates for the transformations shown in Schemes I-III
may contain functional groups (for example. amino, hydroxy or carboxy) which are not immediately compztible with the conditions of the given reaction. In such cases, these groups may be protected with a suitable protective group, and this protective group removed subsequent to the transformation to give the original functionality using well know procedures such as those illustrated in T.W. Greene and P.G. M. Wuts, Protective Groups in 10 Organic Synthesis. Second Edition, John Wiley & Sons, Inc., 1991.
The compounds used as initial starting materials in this invention may be purchased from commercial sources or alternatively are readily synthesized by standard procedures which are well know to those of ordinary skill in the art.
Some of the compounds of formula I may exist as stereoisomers, and the invention 15 includes all active stereoisomeric forms of these compounds. In the case of optically active isomers, such compounds may be obtained from corresponding optically active precursors using the procedures described above or by resolving racemic mixtures. The resolution may be carried out using various techniques such as chromatography, repeated recrystallization of derived asymmetric salts, or derivatization, which techniques are well known to those of 20 ordinary skill in the art.
The compounds of formula I which are acidic or basic in nature can form a wide variety of salts with various inorganic and organic bases or acids, respectively. These salts must be pharmacologically acceptable for administration to mammals. Salts of the acidic compounds of this invention are readily prepared by treating the acid compound with an 25 appropriate molar quantity of the chosen inorganic or organic base in an aqueous or suitable organic solvent and then evaporating the solvent to obtain the salt. Acid addition salts of the basic compounds of this invention can be obtained similarly by treatment with the desired inorganic or organic acid and subsequent solvent evaporation and isolation.
The compounds of the invention may be labeled in a variety of ways. For example.
the compounds may be provided as radioactive isotopes; for example, tritium and the ~4C-isotopes. Similarly, the compounds may be advantageously joined, covalently or SUBSTITUTE SHEET (RULE 26) noncovalently, to a wide variety of joined compounds which may provide pro-drugs or function as carriers, labels, adjuvents, coactivators, stabilizers, etc.
Hence, compounds having the requisite structural limitations encompass such compounds joined directly or indirectly (e.g. through a linker molecule), to such joined compounds.
A wide variety of indications may be treated, either prophylactically or therapeutically, with the compounds and compositions of the present invention.
For example, the subject compounds and compositions have been found to be effective modulators of cell proliferation. Limitation of cell growth is effected by contacting a target cell, in or ex vivo, with an effective amount of one or more of the subject compositions or compounds. Compounds may be assayed for their ability to modulate cellular proliferation using cell and animal models to evaluate cel! growth inhibition and cvtotoxicity, which models are known in the art, but are exemplified by the method of S.A. Ahmed et al. ( 1994) J.
Immunol. Methods I 70: 211-224, for determining the effects of compounds on cell growth.
Conditions amenable to treatment by the compounds and compositions of the present invention include any state of undesirable cell growth, including various neoplastic diseases, abnormal cellular proliferations and metastatic diseases, where any of a wide variety of cell types may be involved, including cancers such as Kaposi's sarcoma, Wilms tumor, lymphoma, leukemia, myeloma, melanoma. breast, ovarian, lung, etc, and others such as cystic disease, cataracts, psoriasis, etc. Other conditions include restenosis, where vascular smooth muscle cells are involved, inflammatory disease states. where endothelial cells, inflammatory cells and glomeruiar cells are involved, myocardial infarction.
where heart muscle cells are involved, glomerular nephritis, where kidney cells are involved, transplant rejection, where endothelial cells are involved, infectious diseases such as HIV infection and malaria, where certain immune cells and/or other infected cells are involved, and the like.
Infectious and parasitic agents per se (e.g. trypanosomes, fungi, etc) are also subject to selective proliferative control using the subject compositions and compounds.
Many of the subject compounds have been shown to bind to the 1J-subunit of tubulin and interfere with normal tubulin function. Hence, the compounds provide agents for modulating cytoskeletal structure and/or function. Preferred compounds bind irreversibly or covalently, and hence provide enhanced application over prior art microtubule disruptors such as colchicine. The compositions may be advantageously combined and/or used in SUBSTITUTE SHEET (RULE 26) combination with other antiproliferative chemotherapeutic agents. different from the subject compounds (see Margolis et al. (1993) US Pat No. 5.262.409). Additional relevant literature includes: Woo et al. (1994) W094/08041; Bouchard et al. (1996) W096/I3494;
Bombardelli et al. (1996) W096/11184; Bonura et al. (1992) W092/15291.
ANALYSIS
The subject compositions were demonstrated to have pharmacological activity in in vitro and in vivo assays, e.g. are capable of specifically modulating a cellular physiology to reduce an associated pathology or provide or enhance a prophylaxis. Preferred compounds display specific toxicity to various types of cells. Certain compounds and compositions of the present invention exert their cytotoxic effects by interacting with cellular tubulin. For certain preferred compounds and compositions of the present invention. that interaction is covalent and irreversible. For example, exposure of a wide variety of tissue and cell samples.
e.g. human breast carcinoma MCF7 cells, to tritiated forms of these preferred compounds, e.g.
Compound 7 (Example 72), results in the irreversible labeling of only one detectable cellular protein, which was found to be tubulin. This protein is a key component of microtubules, which constitute the cytoskeleton and also play critical roles in many other aspects of the cell's physiology, including cell division. The labeling of tubulin by the subject preferred compounds is also shown to be dose-dependent. The site of covalent binding on tubulin is identified as Cysteine-239 on the 13-tubulin chain. The same Cys-239 residue is selectively covalently modified when present in a wide variety of Cys-239 containing 13-tubulin petides (e.g. Ser-234 to Met-267) provided in vitro or in vivo. Consistent with the ability of these compounds to bind to 13-tubulin, treatment of a wide variety of cell and tissue types with various concentrations of the compounds resulted in widespread. irreversible disruption of the cytoskeleton of most cells.
As described inter alia in Luduena ( 1993) Mol Biol of the Cell 4, 445-457, tubulin defines a family of heterodimers of two polypeptides, designated a and 13.
Moreover, animals express multiple forms (isotypes) of each a and 13 polypeptides from multiple a and 13 genes. Many f3 isotypes comprise a conserved cysteine, Cys-239 (of human 132 tubulin:
because of upstream sequence variations, the absolute position of Cys-239 is subject to variation, though Cys-239 is readily identified by those in the art by its relative position (i.e.
SUBSTITUTE SHEET (RULE 26) context within encompassing consensus sequence, e.g. at least 8, preferably 12, more preferably 16; most preferably 20 residue consensus peptide region of the isotype or fragment thereof, which region contains Cys-239). By selective binding to Cys-239 is meant that Cys-239 is preferentially bound relative to all other residues, including cysteins of the protein, by at least at least a factor of 2, preferably 10, more preferably 100, most preferably 1,000. In a particularly prefered embodiment, Cys-239 is substantially exclusively and:
preferably exclusive bound. By selective binding to or modification of tubulin is meant that tubulin is preferentially modified relative to all other,proteins, by at least a factor of 2, preferably 10, more preferably 100, most preferably 1,000. In a particularly prefered embodiment, tubulin is substantially exclusively and preferably exclusive modified.
Compounds may be evaluated in vitro for their ability to inhibit cell growth.
for example, as described in S.A. Ahmed et al. (1994) J. Immunol. Methods 170:211-224. In addition, established animal models to evaluate antiproliferative effects of compounds are known in the art. For example, several of the compounds disclosed herein are shown to I 5 inhibit the growth of human tumors, including MDR and taxo~andlor vinblastine-restistant tumors, grafted into immunodeficient mice (using methodology similar to that reported by J.
Rygaard and. CØ Povlsen ( 1969) Acta Pathol. Microbiol. Scand. 77:758-760, and reviewed by B.C. Giovanella and J. Fogh (1985) Adv. Cancer Res. 44:69-120.
FORMULA~'ION AND ADMINISTRATION
~.. The invention provides methods of using the subject compounds and compositions to treat disease or provide medicinal prophylaxis, to slow down and/or reduce the growth of tumors, to treat bacterial infections, etc. These methods generally involve contacting cells with or administering to the host an effective amount of the subject compounds or pharmaceutically acceptable compositions.
The compositions and compounds of the invention and the pharmaceutically acceptable salts thereof can be administered in any effective way such as via oral, parenteral or topical routes. Generally, the compounds are administered in dosages ranging from about 2 mg up to about 2,000 mg per day, although variations will necessarily occur depending on the disease target, the patient. and the route of administration. Preferred dosages are administered orally in the range of about 0.05 mg/kg to about 20 mg/kg, more preferably in the range of WO 9$/05315 PCT/US97/12720 about 0.05 mg/kg to about 2 mg/kg, most preferably in the range of about 0.05 mg/kg to about 0.2 mg per kg of body weight per day.
In one embodiment, the invention provides the subject compounds combined with a pharmaceutically acceptable excipient such as sterile saline or other medium, water, gelatin. an oil, etc. to form pharmaceutically acceptable compositions. The compositions and/or compounds may be administered alone or in combination with any ,convenient carrier, diluent, etc. and such administration may be provided in single or multiple dosages.
Useful carriers include solid, semi-solid or liquid media including water and non-toxic organic solvents.
In another embodiment, the invention provides the subject compounds in the form of a pro-drug, which can be metabolically converted to the subject compound by the recipient host. A wide variety of pro-drug formulations are known in the art.
The compositions may be provided in any convenient form including tablets.
capsules, lozenges, troches, hard candies, powders, sprays, creams, suppositories, etc. As such the compositions, in pharmaceutically acceptable dosage units or in bulk, may be incorporated into a wide variety of containers. For example, dosage units may be included in a variety of containers including capsules, pills, etc.
The compositions may be advantageously combined and/or used in combination with other antiproliferative therapeutic or prophylactic agents, different from the subject compounds. In many instances, administration in conjunction with the subject compositions enhances the efficacy of such agents. Exemplary antiproliferative agents include cyclophosphamide, methotrexate, adriamycin, cisplatin, daunomycin, vincristine, vinblastine.
vinarelbine, paclitaxel, docetaxel, tamoxifen, flutamide, hydroxyurea, and mixtures thereof.
The compounds and compositions also find use in a variety of in vitro and in vivo assays, including diagnostic assays. In certain assays and in in vivo distribution studies, it is desirable to used labeled versions of the subject compounds and compositions, e.g. radioligand displacement assays. Accordingly, the invention provides the subject compounds and compositions comprising a detectable label. which may be spectroscopic (e.g.
fluorescent), radioactive, etc.
The following examples are offered by way of illustration and not by way of limitation.
SUBSTITUTE SHEET (RULE 26) EXAMPLES
iH NMR spectra were recorded on a Varian Gemini 400MHz NMR spectrometer.
Significant peaks are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constants) in Hertz, number of protons.
Electron Ionization 5 (EI) mass spectra were recorded on a Hewlett Packard 5989A mass spectrometer. Fast Atom Bombardment (FAB) mass specvoscopy was carried out in a VG analytical ZAB 2-SE
high field mass spectrometer. Mass spectroscopy results are reported as the ratio of mass over charge, and the relative abundance.of the ion is, reported in parentheses.
10 Example 1 NMe2 F F ~
~N
F ~ F H
F
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene. To N,N dimethyl-1,4-phenyldiamine dihydrochloride (3g, 14.6mmo1) suspended in pyridine (SOmL) at 0 ~C under argon was added dropwise pentafluorophenylsulfonyl chloride (2.38mL, l6mmol). The reaction mixture was stirred for 30 min at 0 ~C and allowed to wane to ambient temperature. The reaction mixture was stirred at room temperature for 3h. The volume of the mixture was then reduced to 10 mL under reduced pressure. The mixture was diluted with ethyl acetate and the reaction quenched with water. The layers were separated and the aqueous layer extracted twice with ethyl acetate. The organic layers were combined and washed with brine and dried with MgS04. The solvent was evaporated and the residue purified by chromatography on silica, eluting with CH,CI,. The title product was obtained as a white solid in 63% yield (3_4g).'H NMR (CDC13): 7.01(d,J=8.9Hz, 2H), 6.77(s, 1H), 6.59(d, .~8.3Hz, 2H), 2.92ppm(s, 6H). FAB m/z (relative abundance): 367( 100%.
M+H+), 135(30%). 121(25%). Anal. calcd. for C~4H~1FSNZO.,S: C 45.95, H 3.03. N 7.65.
Found C
45.83, H 2.99, N 7.62 Ex ~~e 2 NMe2 F
F / S~N \
F \ F
F
3-(N,N Dimethylamino)-1-pentafluorophenylsulfonamidobenzene. ~H NMR (CDCl3):
7.12(t, J--8Hz, 1 H), 7.05(s, 1 H), 6.57{s, 1 H) 6.53(d, J--8Hz, 1 H), 6.40(d, .I 8Hz, 1 H), 2.94ppm (s, 6H). FAB miz: 366 (100%, M+). The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 3-(N,IV dimethylamino)aniline.
Example 3 F
1,2-Ethylenedioxy-4-pentafluorophenylsulfonamidobenzene. ' H NMR {CDC13):
6.97(s, 1 H), 6.76(d, J--8.6Hz, 1H), 6.72(d, J--2.6Hz, 1H), 6.62(dd, J--8.6, 2.6Hz, 1H), 4.21ppm (s, 4H).
FAB m/z: 381 ( 100%, M+H+). Anal calcd. for C ~ 4HgF 5N04S: C 44.09, H 2.12, N
3.68, S
8.39. Found: C 43.83, H 2.19, N 3.62, S 8.20. The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 3,4-ethylenedioxyaniline.
F O
O
F / S~N ~ O
F \ F H
SUBSTITUTE SHEET (RULE 26) Example 4 / O
F F OSO w / ~N O
s F F H
F
1,2-Methylenedioxy-4-pentafluorophenylsulfonamidobenzene. 1H NMR (CDC13):
6.8s(s, 1H), 6.78 (s, 1H), 6.70(d,J--8Hz, 1H), 6.s7(d, J--8Hz, IH), s.97ppm(s, 2H).
The compound I O was prepared by a protocol similar to that of example I by replacing N,N dimethyl-1,4-phenyidiamine dihydrochloride with 3,4-methylenedioxyaniline.
Example 5 OMe is F O~ ~O /
F / S~ N ~ OMe F ~ F H
F
20 I,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene. ~H NMR (CDC13):
6.98(s, 1H), 6.85(d, 1H), 6.74(d, 1H), 6.60(dd, IH), 3.8s(s, 3H), 3.83ppm (s, 3H). EI, m/z:
383(s0, M+).
1s2(100). The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 3,4-dimethoxyaniline.
SUBSTITUTE SHEET (RULE 26) .example 6 OMe F O
F / S~ N ~ OH
F \ F H
F
2-Hydroxy-I-methoxy-4-pentafluorophenylsulfonamidobenzene. 'H NMR (CDCl3):
6.93(s, 1H), 6.7-6.8(m, 3H), 5.68(bs, 1H), 3.85ppm(s, 3H). EI, m/z: 333(20, M+), 138(100). mp 118-120 °C. The compound was prepared by a protocol similar to that of example 1 by replacing N,N-dimethyl-1,4-phenyldiamine dihydrochloride with 3-hydroxy-4-methoxyaniline.
2o F
2-Fluoro-1-methoxy-4-pentafluorosulfonamidobenzene.
~H NMR (DMSO) 11.15 (broad s. 1 H), 7.13 (t, J--9Hz, I H), 7.02 (dd, J--9.5 2.5 Hz, 1 H), 6.94ppm (dd, J--8.8 l.SHz, 1H), 3.79ppm (s, 3H). EI, m/z: 371 (20, M+), 140 (100). Anal.
calcd. for C ~ 3H7HF6N ~ 03S ~ : C 42.06, H 1.90, N 3.77, S 8.64. Found: C
42.19. H 1.83, N
3.70, S 8.60. Mp 118-119°C. The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 3-fluoro p-anisidine.
OMe F Oy i O
F ~ S.N ~. F
F ~ F H
SUBSTITUTE SHEET (RULE 26) Exam~e 8 s F
4-Methoxy-1-pentafluorophenylsulfonamidobenzene. 'H NMR (CDC13): 6.99 (s, 1H), 6.96(d, .I--4Hz, 2H), 6.88 (d, J--4Hz, 2H), 3.83ppm(s, 3H). EI, m/z: 3s3 (60, M+), 122 (100).
M.p. 102-103 °C. The compound was prepared by a protocol similar to that of example 1 by replacing N,N-dimethyl-1,4-phenyldiamine dihydrochloride with 4-methoxyaniline.
Exam 1p a 9 is F F
~N OH
F ~ F H
F
3-Hydroxy-1-pentafluorophenylsulfonamidobenzene. iH NMR (CD30D}: ?.ls(t, J--8.lHz, 1H), 6.6?(t, .l 2.2Hz, 1H) 6.60(dd, J--l.3Hz, ?.BHz, 1H), 6.s2ppm (dd, J--2.4Hz 8.3Hz, IH). EI, m/z: 339 (80, M~), 2s6 (s0), 81 (100). The compound was prepared by a protocol similar to that of example 1 by replacing N, N dimethyl-1,4-phenyldiamine dihydrochloride with 3-hydroxyaniline.
/ OMe F
F / S~ N W
F ~ F H
SUBSTITUTE SHEET (RULE 26) Ex~TI In a 10 / OH
F F s / ~N
I
F F H
F
4-Hydroxy-1-pentafluorosulfonamidobenzene. 'H NMR (CD30D): 6.95(d, J--8.9Hz, 2H), 6.65ppm (d, J--8.9Hz, 2H). EI, m/z: 339 (30, M+). The compound was prepared by a 10 protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 4-hydroxyaniline.
Example 11 Me is F O s o / I ~N Me F \ F H
F
I,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene. tH NMR (CDC13): 7.03(d, J=7.9Hz, 20 1H), 6.92(s, 1H), 6.85-6.82(m. 2H), 2.18(s, 3H), 2.16ppm(s. 3H). The compound was prepared by a protocol similar to that of example 1 by replacing N,N-dimethyl-1,4-phenyldiamine dihydrochloride with 3,4-dimethylaniline.
SUBSTITUTE SHEET (RULE 26) E~ple 12 F
4-(N>N Diethylamino)-1-pentafluorophenylsulfonamidobenzene. ~H NMR (CDC13):
6.93(d, J--8.8Hz, 2H), 6.78(s, 1 ), 6.45(d, J--8.7Hz, 2H), 3.25(dd, J--7.OHz, 7.3Hz,4H), 1.1 Oppm (t, J--7.2Hz, 6H). The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyidiamine dihydrochloride with 4-(N,N
diethylamino)aniline.
~,xample 13 is F F ~ S ~ ~ I
/ ~N
I
F \ F H
F
4-Amino-1-pentafluorophenylsulfonamidobenzene. 1H NMR (CDCl3): 6.82(d, J--8.7Hz, 2H), 6.49ppm(d, J--8.7Hz. 2H). EI, mlz: 338(7. M+), 107(100). 80(40). The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 1,4-diaminobenzene.
NEt2 F
F / S~ N w I
F ~ F H
SUBSTITUTE SHEET (RULE 26j Examnl~,4_ F
F oSo ~N
H
F'~ F
F
Pentafluorophenylsulfonamidobenzene. 'H NMR (CDC13): 7.30(d, J--8Hz, 2H), 7.13-7.2(m, 3H), 7.Oppm(s, 1H). EI, m/z: 323(90, M+), 92(100). The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with aniline.
Example 1 S
H
N
F /
I ~N
F / S~ N
I
F ~ F H
F
5-Pentafluorophenylsulfonamidoindazole. 1H NMR (CD30D): 7.98(s, 1H), 7.69(s, 1H), 7.47(d, J--8.3Hz, 1H), 7.23ppm(d, J--8.3Hz, 1H). EI m/z: 364(50, M+H+), 133(100). The compound was prepared by a protocol similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 5-aminoindazole.
SUBSTITUTE SHEET (RULE 2fi) Exam~Ie 16 H
N
F ~\ /~ I
F s, ~ /
F \ F H
F
5-Pentafluorophenylsulfonamidoindole. /H NMR (CDC13): 8.2(s, 1H), 7.43(s, 1H), 7.3(d, J--8 Hz, 1 H'), 7.22(s, 1 H)}, 6.98 (d, J--8 Hz, 1 H), 6.92ppm (s, 1 H), 6.50ppm(s, 1 H). EI m/z:
362(M+), 131 ( 100). The compound was prepared by a protocol similar to that of example 1 by replacing N.N-dimethyl-1,4-phenyldiamine dihydrochloride with 5-aminoindole.
ExamRle 17 2o F
4-(N,N Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene.
4-(N,N Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene (100mg, 0.273mmo1) was dissolved in dry THF (2.5mL) and to the system was added under N2 at room temperature a 1M solution of lithium bis(trimethylsilyl)amide (0.274mL). The reaction mixture was stirred for 10 min followed by addition of MeI (65mg, 0.028mL). The reaction mixture was stirred overnight, the solvent was evaporated under reduced pressure and the crude product purified by HPLC using silica as the stationary phase and eluting with 20%EtOAc/Hex (v/v) to afford the product as a white solid in 60% yield (62mg). EI m/z: 380(35. M+), 149(100). 'H NMR
(CD30D) .7.05(d, J=8Hz, 2H), 6.68(d, J=8Hz, 2H), 3.33(s. 3H) 2.93(s, 6H).
Anal. calcd. for C15H13FSS02N,,: C 47.37, H 3.45, N 7.37. Found: C 47.37. H 3.49, N 7.32.
NMe2 F F ~S~ ~
~N
F ~ F Me SUBSTITUTE SHEET (RULE 26) Exa ple 18 / OH
F F O SO ~
/ I ~N OH
F ~ F H
F
1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene.
1-Hydroxy-2-methoxy-4-pentafluorophenylsulfonamidobenzene (250mg, 0.678mmol) was suspended in dry CH,,CI., (~mL) at 0 ~C under nitrogen. To the mixture was added BBr3 as a 1M solution in CH2C1,, (0.746mmol, l.leq.). The mixture was warmed to ambient temperature and stirred overnight. The reaction mixture was poured over ice (75mL) and extracted 3 times with 30 mL portions of CH,,CI,,. The organic layer was dried with MgS04_ I 5 and the solvent was evaporated. The crude product was purified by chromatography over silica eluting with 30% (v/v) EtOAc/Hex to afford the product as a white solid in 41 % yield (98mg): ' H NMR (DMSO): 10.63(s, 1 H), 9.15(s, 1 H), 8.91 (s, 1 H), 6.61 (d, J--9Hz, 1 H), 6.58(d, J--3Hz, 1H), 6.39ppm(dd, J-- 9Hz 3Hz, 1H).
SUBSTITUTE SHEET (RULE 26) ~.~ l F OEt F / S~tv F ~ F H
F
4-Ethoxy-1-pentafluorophenylsulfonamidobenzene. To a stirred solution ofp-phenetidine 10 (0.100g, 0.729mmol) in dimethylformamide (3.65 mL} at 25 ~C was added pentafluorophenyl sulfonyl chloride (0.135mL, 0.91 lmmol), followed by sodium carbonate (0.116g, 1.09mmol), and the reaction mixture was stirred for 18 hours. The reaction mixture was diluted with ethyl acetate (SOmL) and washed with 20% ammonium chloride (2 x 20mL) and saturated sodium chloride (2 x 20mL). The organic layer was dried (sodium sulfite), and 15 the ethyl acetate was removed under reduced pressure to yield a reddish-brown oil. Column chromatography (3:1 ethyl acetate/hexane) yielded the title compound (0.222g, 83%). 1H
NMR (CDCl3) 7.08 (d, J= 9Hz, 2H), 7.04 (s, 1H), 6.80 (d, J-- 9Hz, 2H), 3.96 (q. J--7Hz, 2H}, 1.37 ppm (t, J--7Hz, 2H). IR (neat) 3000-3600, 1750 cm-~. EI m/z :
367(M+), 154, 136.
The compounds of Examples 20 through 26 were prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with the appropriate amine.
SUBSTITUTE SHEET (RULE 26) F~xamnle 20 OMe F
F O~S O
/ I ~N OMe F \ F H
F
3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene . The compound was prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with 3,5-dimethoxyaniline. 1H NMR (CDC13) 6.91(s. 1H), 6.32(s. 2H), 6.25(s, 1H), 3.72ppm(s, 6H).
Example 21 F O~ ~O /
F S
/ I N OEt F ~ F
F
3-Ethoxy-1-pentafluorophenylsulfonamidobenzene . The compound was prepared by a protocol similar to that of Example 19 by replacingp-phenetidine with 3-ethoxyaniline. ~H
NMR (CDCl3) 7.35 (t, J = 8Hz, I H), 7.21 ( s, 1 H), 6.92( s, 1 H), 6.86(d, J--8Hz, 1 H), 6.83(d, J--BHz, 1H), 4.15( q, J--6Hz. 2H), 1.56ppm ( t, J 6Hz, 3H).
SUBSTITUTE SHEET (RULE 26) Exa~ngle 22 / L
F F oso w / L ~N OH
H
F ~ F
F
7-Hydroxy-2-pentafluorophenylsulfonamidonaphthalene. The compound was prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with 2-amino-7-hydroxynaphthalene. ' H NMR (CDC13) 8.15 ( t. J = 8Hz, 1 H), 7.55( d. J--8Hz, 1H), 7.44 (s, 1H), 7.42 (d, J 8Hz, 1H), 7.40 (s, 1H), 6.88ppm (q, J--8Hz, 1H).
ExamQle 23 F F OSO w L
/ L ~ N' OPh F \ F H
2o F
3-Phenoxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with 3-phenoxyaniline. ~H
NMR {CDCl3) 7.34 ( t, J = BHz, 2H), 7.26 ( t, J--8Hz, 1 H), 7.16 ( t, J--8Hz, 1 H), 6.94 (d, J--BHz, 2H), 6.86 ( d, J--8Hz, 1 H), 6.82 ( d, J 8Hz, 1 H}, 6.74 (s, 1 H ).
SUBSTITUTE SHEET (RULE 26) E~camRle F
F O~S O
/ 'N OMe ~
F F H
F
3-Methoxy-I-pentafluorophenylsulfonamidobenzene. The compound was prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with 3-methoxyaniline. ~H
NMR (CDC13) 7.20 (d, J= 8Hz. 1H, ), 6.95 (s, 1H), 6.78 ( d, J--8Hz, 1H,), 6.70 ( t, J--8Hz, I H), 3.79 ppm (s, 1 H).
Example 25 ~O
F O O , N
% I
F / S'N
F ~ F
F
4-(I-Morpholino)-1-pentafluorophenylsulfonamidobenzene. The compound was prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with 4- .(I-morpholino)aniline. ~1-~ NMR (CDCl3) 7.09 (d, J= 8Hz, 2H), 6.85 (d, J--8Hz, 2H}, 3.85 (t, J--8Hz, 4H), 3.15ppm (t, J--8Hz, 4H).
SUBSTITUTE SHEET (RULE 26) Exam IP a 26 OMe / OMe F O\ /O
F / S~N \ OMe F \ F H
F
5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene. The compound was prepared by a protocol similar to that of Example 19 by replacing p-phenetidine with 3,4,5-trimethoxyaniline. ~ H NMR (CDC13) 8.14 (s, 1 H), 6.46 (s, 2H), 3.69 (s, 6H), 3.59 (s, 3H).
Example 27 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene .
1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene.
5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene.
1,2,3-Methoxy-5-pentafluorophenylsulfonamidobenzene (269mg, 0.65mmo1) was suspended in dry CH,,CI., (SmL) at 0 ~C under nitrogen. To the mixture was added BBr3 as a 1 M
solution in CH2C1~ (3.26mmo1, Seq.). The mixture was warmed to ambient temperature and stirred overnight. The reaction mixture was poured over ice (75mL) and extracted 3 times with 301nL portions of CH,,CI,,. The organic layer was dried with MgS04, evaporated. and the residue was subjected to chromatography over silica eluting with 30% (v/v) EtOAc/Hex to afford the three products. The compounds of Examples 28 and 29 were prepared in a manner similar to that described above beginning with the product of Example 20 and treating it with BBr3.
SUBSTITUTE SHEET (RULE 26) OMe / OH
F O\ /O I
F / S~N ~ OMe H
F ~ 'F
F
1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene.
'H NMR (CDC13) 10.85 (s, 1H), 8.31 (s, IH), 6.41 (s, 2H), 3.66 ppm (s, 6H).

1,2-Dihydroxy-3-methoxy F
-5-pentafluorophenylsulfonamidobenzene. 1H NMR (CDCl3) 10.73 (s, IH), 8.31 (s, 1H), 6.27 (s, 1H), 6.26 (s, 1H), 3.66 ppm (s, 3H).
OH
/ OH
F O\ /~ I
F / S~N ~ OH
F w F H
F
5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene. iH NMR (CDC13) 11.0 (s, 1H), 9.03 (s, 2H), 8.06 (s, 1H), 6.13 ppm (s, 2H).
OMe / OH
F F s I ~N OH
F ~ F H
SUBSTITUTE SHEET (RULE 26) Exam l OMe F
F ~ S~N \ OH
F ~ F H
F
3-Hydroxy-S-methoxy-1-pentafluorophenylsulfonamidobenzene. 'H NMR (CDCl3) I
1.2 (s, 1 H), 9.63 (s. 1 H), 6.23 (s, 1 H), 6.21 (s, 1 H), 6.08 (s, 1 H), 3.63 (s, 3H).
Exam In a 29 OH
IS F O O
F / S~N ~ OH
F ~ F H
F
3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene. 'H NMR (CDC13) 7.15 (s, IH), 6.25 (s, 2H), 6.15 (s, 1H), 5.31 (s, 2H).
SUBSTITUTE SHEET (RULE 26) E a 0 F
OMe F O\ /O
s F / S~N W
Me F ~ F
F
2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene. Prepared using a procedure similar to that of Example 18 replacing 4-(N,N dimethylamino)-1-pentafluorophenylsulfonamidobenzene with the appropriate non-substituted sulfonamide (product of Example 7). ~H NMR (CDCl3): 6.97-6.94(m, 2H), 6.89(t, J--9Hz, 1H), 3.87(s, 3H). 3.35ppm (t, J=1Hz). EI m/z: 38s(20, M+), 1s4(100). Anal.
calcd. .for C~4HyF6N03: C 43.64. H 2.3s, N 3.64. Found C 43.55, H 2.38, N
3.65.
is Example 31 Br OMe F F OvS O ~
~N
F \ F H
F
2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene. ~H NMR (CDC13):
7.35(d, J--3Hz, 1H), 7.15(dd. J--9Hz, 3Hz, 1H), 6.97 (s, 1H), 6.81(d, J--9Hz, 1H), 3.88 ppm (s, 3H).
EI m/z: 433(3s, MT), 202(100). The compound was prepared by a protocol similar to that of example 1 by replacing N N dimethyl-l ,4-phenyldiamine dihydrochloride with 3-bromo-4-methoxvaniline.
SUBSTITUTE SHEET (RULE 26) Example 32 CI
F / OMe O
F / S. N
I
F \ F H
F
2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene. iH NMR (CDC13):
7.19(d, J--3Hz, 1H), 7.08(dd, J--9Hz, 3Hz, 1H), 7.01 (s, 1H), 6.84(d, J--9Hz, 1H), 3.85 ppm (s, 3H).
EI m/z(rel. abundance): 387(10, M+). 156(100). The compound was prepared by a protocol similar to that of example I by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with 3-chloro-4-methoxyaniline.
Exar 1p a 3 3 / NMe2~HCI
F F OSO w / ~N
F \ F
F
4-(N,N Dimethylamino)-I-pentafluorophenylsulfonamidobenzene hydrochloride.
4-(N,N Dimethylamino}-1-pentafluorophenylsulfonamidobenzene (2g, S.~mmol) was dissolved in lSmL of diethyl ether at ambient temperature under nitrogen.
Gaseous HCl was bubbled into the reaction mixture for 5 min. The mixture was filtered and the resulting solid washed twice with lSmL portions of ice cold diethyl ether to afford the product as a white solid (1.89g, 86% yield). 'H NMR (CD30D): 7.62(dd, J--9.OHz, l.6Hz. 2H), 7.44(dd, J 9.OHz, l.6Hz, 2H), 3.28ppm(s, 6H). FAB m/z: 367(100%, M+H+), 135(90%), 121(45%).
Anal. calcd. for Ci4H~3C1F5N202S: C 41.79, H 3.01, N 6.97, S 7.95. Found C
41.71, H 3.05, N 7.01, S 7.96.
SUBSTITUTE SHEET (RULE 26) F
F
F O"O
F ~ S~N
F ~ F H
F
3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that of example 1 by replacing N,N-dimethyl-1,4-phenyldiamine dihydrochloride with 3,4-difluoroaniline. 'H NMR (CDC13) 7.13 (m, 3H), 6.9lppm (m, 1H).
EI, m/z (relative abundance) : 359 (20), 128 (100). Anal. calcd. for C~3H~F7NO.,S: C 40.12.
H 1.12, N 3.90. Found: C 40.23, H 1.17, N 3.89.
Example 35 O O , I OCF3 F
,, ,, F ~ S~N
F ~ F H
F
4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that of example 1 by replacing N,N-dimethyl-1,4-phenyldiamine dihydrochloride with 4-(trifluoromethoxy)aniline. 1H NMR (CDC13) 7.18ppm (m, 4H). E1, m/z (relative abundance) : 407 (20), 176 (100). Anal. calcd. for C13HSFgN03S:
C 38.34, H
1.24, N 3.44. Found: C 38.33, H 1.30, N 3.43.
SUBSTITUTE SHEET (RULE 26) Example 36 N CI
F ~
F ~ 'S.N
F ~ F H
F
2-Chloro-5-pentafluorophenylsulfonamidopyridine. The compound was prepared in a manner similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine 10 dihydrochloride with 5-amino-2-chloropyridine. H NMR (DMSO-d6): 8.18 (d, J=2.68 Hz, 1H), 7.64 (dd, J=8.75. 2.89 Hz. 1H), 7.SOppm (d, J=8.75 Hz. 1H). EI m~'z 358 (20. M+).
127 (100). Anal. calcd. for C~ ~H4C1F5N,02S: C 36.83, H 1.12. N 7.81, S 8.94, Cl 9.90.
Found: C 37.00, H 1.16. N 7.78. S 8.98, C1 10.01. White crystals with M.P.=144-145 ~C.
15 Example 37 OMe F O. ,O
F ~ S~N ~ OH
F ~ F OH
F
2-Hydroxy-1-methoxy-4-(N-(5-hydroxypentyl)-pentafluorophenylsulfonamido)benzene.
N (5-hydroxypentyl)-2-hydroxy-1-methoxy-4-aminobenzene was prepared by reductive amination of 5-amino-2-methoxy phenol with glutaric dialdehyde with NaBH4 in MeOH.
2-Hydroxy-1-methoxy-4-(N-(5-hydroxypentyl)-pentafluorophenylsulfonamido)benzene was prepared in a manner similar to that of example 1 by replacing N,N dimethyl-1,4-phenyldiamine dihydrochloride with N (5-hydroxypentyl)-2-hydroxy-1-methoxy-4-aminobenzene. ~H NMR (CDC13): 6.78(d, J=8.6 Hz. 1H), 6.71(dd.
J=8.59, 2.48 Hz. 1H), 6.63(d, J=2.48 Hz, 1H), 3.88(s, 3H), 3.7(t, J=6.8 Hz, 2H), 3.6(t, J=6.39 Hz, 2H), l.~ppm (m, 6H). Anal. calcd. for C~gHIgF5NO5S: C 47.47, H
3.98, N 3.08, S 7.04. Found: C 47.47, H 4.04, N 3.11, S 6.97. White crystals with M.P.=118.
SUBSTITUTE SHEET (RULE 26) WO 98105315 PCT/US97t12720 / O~Bu F O, ,O
F ~ S~N
F I / F H
F
4-( 1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene.
The compound was prepared in a manner similar to example 46 by replacing 3-chloroaniline with 4-t-butoxyaniline. 4-t-Butoxyaniline was prepared by the method of Day (J. Med.
Chem. 1975, 18, 1065). 1H NMR (CDC13): d 7.07 (m, 2), 6.92 (m, 2), 6.88 (m, 1), 1.31 (s, 9). MS (EI): mia 395 (1, Mt), 339 {28), 108 (100). Anal. Calcd. for C~6H14FSN03S: C, 48.61; H, 3.57; N, 3.54; S. 8.11. Found: C. 48.53; H. 3.60: N. 3.50; S. 8.02.
Example 39 F O O ~ OMe '' ' F ~ S~N ~ OH
F ~ F hi Br F
1-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared by bromination of the compound of example 6 with N
bromosuccinimide in dichloromethane. 1H NMR (CDC13) 7.28 (br s, 1H), 7.21 (d, .I--9Hz, 1H). 6.80 (d, J--9Hz, 1H), 6.05 (s, 1H), 3.89ppm (s, 3H). EI, m/z (relative abundance) : 449 {25), 447 (25), 218 (100), 216 (100). Anal. calcd. for Cl3HgBrF5N04S: C 34.84. H 1.57, N 3.13, S
7.15. Found:
C 34.75, H 1.60, N 3.07, S 7.08.
SUBSTITUTE SHEET (RULE 26j Example 40 Br OMe F O,.O /
F ~
N OH
F ~ F H
F
2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared by bromination of the compound of example 6 with N
bromosuccinimide in dichloromethane. 1H NMR (CDCI3) 7.28 (s, 1 H). 7.16 (br s, 1 H), 6.91 (s, I
H), 5.63 (s, 1H), 3.85ppm (s, 3H). EI, m/z (relative abundance) : 449 (25), 447 (25), 218 (100), 216 (100).
Anal. calcd. for C~3H8BrF5NO~S: C 34.84, H 1.57, N 3.13, S 7.15. Found: C
34.84. H 1.57, N 3.05, S 7.06.
Example 41 Br , OMe F
O~, .O
F ~ S.N ~ I F
F ~ F H
F
1-Bromo-4-fluoro-~-methoxy-2-pentafluorophenylsulfonamidobenzene. The compound was prepared by bromination of the compound of example 7 with bromine water. ' H
NMR
(CDCl3): 7.49 (d, J=11.72 Hz, 1 H), 7.21 (s, 1 H), 7.04 (d, J=8.2 Hz, 1 H), 3.84 ppm (s, 3H).
EI m/z: 449 (20, M+), 451 (20 ), 228 (100), 230 (100). Anal. Calcd. for C13H6BrF6N03S: C
34.69, H 1.34, N 3.11, S 7.12, Br 17.75. Found: C34.76, H 1.29, N 3.05, S
7.12, Br 17.68.
White crystals with M.P.= 109 ~C.
SUBSTITUTE SHEET (RULE 26) WO 9$/05315 PCT/US97/12720 ~g~e 42 OMe F
F I ~ S~N ~ OH
F / F Na F
2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene sodium salt. The compound was prepared by treating the compound of example 6 with an equimolar amount of 1N NaOHtaq~. The mixture was then lyophilized and the residue recrystallyzed from ethyl acetate/ ether. 'H NMR (DMSO) 8.40 (s, IH), 6.57 (d, J=9Hz, 1H), 6.39 (d. J--2Hz. 1H).
6.24 (dd, J--9, 2Hz, 1H), 3.62ppm {s, 3H). Anal. calcd. for C~3H7FSNNa04S: C
39.91, H
1.80, N 3.58, Na 5.88, S 8.19. Found: C 39.79, H 1.86, N 3.50, Na 5.78, S
8.07.
Example 43 / OMe F ~, ,0 F I ~ S~N ~ OH
F / F K
F
2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene potassium salt. The compound was prepared in a manner similar to that of example 42 by replacing IN NaOH
with 1N KOH. 'H NMR (DMSO) 8.30 (br s, IH), 6.~5 (d, J--9Hz, 1H), 6.36 (d, J--2Hz, 1H), 6.2~ (dd, J=9, 2Hz, 1H), 3.61ppm {s, 3H). Anal. calcd. for C13H7FSKNO~S:
C 38.33.
H 1.73. N 3.44, S 7.87. Found: C 38.09, H 1.79, N 3.39. S 7.97.
SUBSTITUTE SHEET (RULE 26) WO 98/05315 53/,~ PCTlLTS97/12720 a~
O
z z-z O;vs ~
u. / ~ ~ c N
Z-J
.a O
f~
O N
ao ~~
c~
-C
H

N

O

/ ~

LL C

M

i O
O ~ (!~ V
LL

M

C_ O
N

Z-J

O 'a O cu M

N
i U

a~
O
/ \ ,~
O
/ \ ~ c o .n z Z-J
C
O N
ao 'L~
M

O

U

,, / \

~ c a =_z o O

~;(1) L~ U

\

G

.n N

N

Z_J

O 'a C
cb M

N

r U

Example 44 F , OMe F ~ S~N ~ F
i F ~ F K
F
2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene potassium salt. The compound was prepared in a manner similar to that of example 43 by replacing the compound from example 6 with example 7. ~ H NMR (DMSO) 6.80 (t, J--1 OHz, 1 H), 6.72 (dd, J 9, 2Hz, 1H), 6.54 (dd, J--9. 2Hz, 1H), 3.68ppm (s, 3H). Anal. calcd. for C~3H6F6KN03S: C
38.15, H 1.48. N 3.42. S 7.83. Found: C 38.09, H 1.51, N 3.35, S 7.73.
M.P.=202-205 °C.
Example 45 F OMe F ~ S~N ~ F
F ~ F Na F
2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene sodium salt. The compound was prepared in a manner similar to that of example 44 by replacing 1N KOH
with 1N
NaOH. ' H NMR (DMSO) 6.80 (t, J=l OHz, 1 H), 6.71 (dd, J--9, 2Hz, 1 H), 6.53 (dd, J 9, 2Hz, 1H), 3.69ppm (s, 3H). Anal. calcd. for C13H6F6NNaO3S: C 39.71, H 1.54, N
3.56, Na 5.85, S 8.15. Found: C 39.56, H 1.62, N 3.49, Na 5.88, S 8.08. M.P. > 250 °C.
SUBSTITUTE SHEET (RULE 26) Exam lie 46 F F ~Sp CI

F
3-Chloro-1-pentafluorophenylsulfonamidobenzene. To a solution of pentafluorophenylsulfonyl chloride (0.15 mL, 1.00 mmol) in MeOH (4 mL) was added 3-chloroaniline (260 mg, 2.04 mmol). After stirring at rt for 1 h, the reaction mixture was 10 concentrated under reduced pressure and the residue was taken up in EtOAc and then filtered through a plug of silica gel. The filtrate was concentrated to give a yellow oil that upon chromatography provided 265 mg (74%) of product. iH NMR (CDCl3): d 7.28-7.24 (m, 1H), 7.21-7.17 (m, 2H), 7.10-7.08 (m. 1H), 7.07 (s, 1H). MS (EI): m/z 357 (42, M+), 258 (76), 126 (87), 99 (100). Anal. Calcd. for C~2HSC1F5N02S: C, 40.30; H, 1.41;
N, 3.92; S, 15 8.96. Found: C, 40.18; H, 1.35; N, 3.84; S, 8.90.

CI
F
20 F ~ S.N /
H
F ~ F
F
4-Chloro-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a 25 manner similar to that described in example 46 by replacing 3-chloroaniline with 4-chloroaniline. 1H NMR (CDC13): d 7.30 (m, 2H), 7.20 (m, 1H), 7.14 (m, 2H).
MS (EI):
m/z 357 (27, M+), 258 (38), 126 (100), 99 (85). Anal. Calcd. for Cl.,H5C1F~NO.,S: C. 40.30:
H, 1.41; N. 3.92; S. 8.96. Found: C. 40.19: H, 1.37; N, 3.87; S, 8.88.
SUBSTITUTE SHEET (RULE 26) WO 98/05315 PCTlUS97112720 Exam lie 48 F
o,, ,p F I ~ S.H ~ N02 F ~ F
F
3-Nitro-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that described in example 46 by replacing 3-chloroaniline with 3-nitroaniline. ~H
NMR (CDC13): d 8.14 (s, 1H). 8.06-8.03 (m, 2H), 7.66-7.63 (m, 1H), 7.55 (m, 1H). MS
(EI): m/z 368 (54, Mt), 137 (70), 91 (100). Anal. Calcd. for C1.,H5FSN,O,~S:
C. 39.14; H, 1.37; N, 7.61; S, 8.71. Found: C. 39.39: H. 1.45; N, 7.46; S. 8.58.
Example 49 F

F ~ OMe I
F I ~ S.H .i F ~ F
F
4-Methoxy-1-pentafluorophenylsuifonamido-3-trifluoromethylbenzene. The compound was prepared in a manner similar to that described in example 46 by replacing 3-chloroaniline with 4-methoxy-3-trifluoromethylaniline which was obtained by the hydrogenation of the corresponding nitro compound. White solid, mp 121-123 °C. 1H NMR
(CDCl3): d 7.43-7.37 (m, 2H), 6.96 (d, J= 8.8, 1H), 3.88 (s, 3H). MS (EI): m/z 421 (16, M+), 190 (100).
Anal. Calcd. for C~4H7FgN03S: C, 39.92; H, 1.67; N. 3.32; S, 7.61. Found: C, 40.17; H, 1.68; N, 3.28; S, 7.67.
SUBSTITUTE SHEET (RULE 26) Exam 1R a 50 OMe F F O..S:O
N
F ~ F
F
4-Methoxy-1-(N (2-propenyl)pentafluorophenylsulfonamido)benzene. To a solution of 4-methoxy-1-pentafluorophenylsulfonamidobenzene (448 mg, 1.27 mmol) in THF (3 mL) was added triphenylphosphine (333 mg, 1.27 mmol) and allyl alcohol (0.09 mL, 1.27 mmoi).
Diethylazodicarboxylate (0.20 mL, 1.27 mmol) was added and the mixture was stirred at rt.
After 1 h, the reaction mixture was poured onto saturated NaCI (10 mL) and extracted with CH,,C12 (3 x 10 mL). The combined organic extracts were washed with saturated NaHC03 (10 mL) and dried (MgSO,t). Concentration followed by flash chromatography (25:25:1/hexanes:CH,,CI,:EtOAc) provided 451 mg (90%) of product as a white solid, mp 59-60 °C. 1H NMR (CDC13): d 7.06 (m, 2H), 6.85 (m, 2H), 5.79 (m, 1H), 5.15 (s, 1H), 5.11 (m, 1H), 4.37 (d, J= 6.3, 2H), 3.80 (s, 3H). MS (EI): m/z 393 (33, M+), 162 (100), 134 (66).
Anal. Calcd. for C~6H»F5N03S: C, 48.98; H, 2.83; N, 3.57: S, 8.17. Found: C, 49.13; H, 3.15; N, 3.63; S, 8.15.
SUBSTITUTE SHEET (RULE 26) Exam l OMe F
F ~ S.N /
F / F
F \
1-(N (3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene. The compound was prepared in a manner similar to that described in example 50 by replacing allyl alcohol with 3-buten-1-ol. White solid, mp 64-66 °C. ~H NMR (CDCl3): d 7.08 (m, 2H), 6.86 (m, 2H), 5.74 (m, 1H), 5.10-5.04 (m, 2H), 3.83 (m, 2H), 3.81 (s, 3H), 2.25 (q, J= 6.9, 2H). MS (EI):
m/z 407 (13, M+). 366 (24), 135 (100). Anal. Calcd. for Ci7H~,~F5N03S: C, 50.13; H. 3.46;
N, 3.44; S, 7.87. Found: C, 50.25; H. 3.51; N, 3.43; S, 7.81.
Example 52 OMe F Ow0 F ~ S~N
F / F
F
4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene. The compound was prepared in a manner similar to that described in example 50 by replacing allyl alcohol with 4-penten-1-ol. Low melting semi-solid. 1H NMR (CDCl3): d 7.08 (m, 2H), 6.87 (m, 2H), 5.74 (m, 1H), 5.02-4.96 (m, 2H), 3.81 (s, 3H), 3.76 (t,J= 7.04, 2H), 2.11 (q, J= 6.9. 2H), 1.60 (pentet, J= 7.3, 2H). MS (EI): mlz 421 (30, M+), 190 (100). Anal. Calcd.
for C~gH16F5N03S: C, 51.31; H, 3.83: N. 3.32; S, 7.61. Found: C, 51.44; H, 3.89;
N, 3.38; S, 7.54.
SUBSTITUTE SHEET (RULE 26) Example 53 F ~ OMe F ~O.S~ ~ /
F I / F OH
F
OH
1-(N (2,3-Dihydroxy propyl)pentafluorophenylsulfonamido)-4-methoxybenzene. To a solution of 4-methoxy-1-(N (2-propenyl)pentafluorophenylsulfonamido)benzene (101 mg, 0.26 mmol) in acetone:water (8:1, 1 mL) at rt was added N-methylmorpholine N oxide (34.0 mg, 0.29 mmol) and Os04 (0.10 mL of 0.16 M solution in H,,O, 1.60 x 10'2 mmol). After stirring at rt for 18 h. the reaction mixture was treated with saturated NaHS03 (5 mL) and allowed to stir at rt. After 1 h, the reaction mixture was poured onto saturated NaHS03 (~ mL) and extracted with CH,,C12 (3 x 10 mL). The combined organic extracts were dried (MgSO~) and concentrated. Flash chromatography (1:1, 1:2/hexanes:EtOAc) afforded 90 mg (83%) of product as a white solid, mp 130-131 °C. 1H NMR (CDC13): d 7.11 (m, 2H), 6.85 (m, 2H), 3.78 (s, .3H), 3.90-3.65 (m, SH). Anal. Calcd. for C~6H13FSNOSS: C. 45.08; H, 3.07; N, 3.29;
S, 7.52. Found: C, 45.09; H, 3.33; N, 3.27; S, 7.46.
SUBSTITUTE SHEET (RULE 26) exam In a 54 OMe F O
F ~ S~N I
5 F ~ F
F
HO
OH
1-(N (3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene. The 10 compound was prepared in a manner similar to that described in example 53 by replacing 4-methoxy-1-(N {2-propenyl)pentafluorophenylsulfonamido)benzene with 1-(N (3-butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene. White solid, mp 126-128 °C. 'H NMR (CDCl3): d 7.10 (m, 2H), 6.88 {m, 2H), 4.13 (m, 1H), 3.96 (m, 1H), 3.81 (s, 3H), 3.78-3.73 (m, 1 H), 3.64 (dd, l, J = 2.9, 10.7, 1 H), 3.47 (dd, J = 7.3, 11.2; 1 H), 15 2.67 (bs, 1 H), 1.92 (bs, 1 H), 1.62 {m, 2H).
Exam l,~e ~ 5 OMe F F OS~ I
20 I ~ N
F ~ F
F OH
OH
25 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene.
The compound was prepared in a manner similar to that described in example 53 by replacing 4-methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene with 4-methoxy-1-{N (4-pentenyl)pentafluorophenylsulfonamido)benzene. White solid.
mp 116-118 °C. ~H NMR (CDC13): d 7.07 (m, 2H), 6.86 (m, 2H}, 3.80 (s, 3H), 3.78 (m, 2H), 30 3.71-3.62 (m, 2H), 3.43 (dd, J= 7.5, 10.8: 1H), 1.90 (bs, 2H), 1.66-1.49 (m, 4H). Anal.
SUBSTITUTE SHEET (RULE 26) Calcd: for ClgH~g F5N05S: C. 47.48; H, 3.98; N. 3.08; S, 7.04. Found: C.
47.58; H, 3.95; N.
3.06; S, 6.95.
exam In a 56 OMe F F O..S:O
N
F ~ F
F
OH
I-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene. To a solution of I-(N (3-butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene (410 mg, I.O1 mmol) in THF (6.5 mL) at -78 °C was added BH3.THF (1.00 mL of a 1 M solution in THF, I.00 mmol). After stirnng at -78 °C for I h and at 0 °C for I h. the reaction mixture was treated with H,,O (20 mL) and sodium perborate (513 mg, 5.14 mmol). After stirring at rt for 2 h, the mixture was poured onto H.,O (20 mL) and extracted with CH.,C1,, (3 x 1 ~ mL).
The combined organic extracts were washed with sat. NaCI (20 mL) and dried (MgS04).
Concentration followed by chromatography (2:1/hexanes:EtOAc) afforded 270 mg (64%) of product as a white solid, mp 88-90 °C. ~H NMR (CDC13): d 7.08 (m. 2H).
6.85 (m, 2H), 3.80 (s, 3H), 3.77 (m, 2H), 3.64 (t, J= 6.0; 2H), 1.63-1.55 (m, 5H), 1.50 (bs, 1H). Anal.
Calcd. for C~7H16FSNO~S: C. 48.00; H, 3.79; N, 3.29; S, 7.54. Found: C, 48.08;
H. 3.76; N, 3.34; S, 7.46.
SUBSTITUTE SHEET (RULE 26) Ex~~le 57 OMe F
F ~ S ~N
I
F ~ F
F
OH
4-Methoxy-1-(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)benzene. The compound was prepared in a manner similar to that described in example 56 by replacing 1-(N-(3-butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene with 4-methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene. White solid.
mp 96-97 °C. ~H NMR (CDCl3): d 7.08 (m, 2H), 6.86 (m, 2H), 3.81 (s, 3H), 3.76 (t, J= 6.8, 2H), 3.62 (t, J= 6.4; 2H), 1.58-1.43 (m, 6H). Anal. Calcd. for ClgHIgF5N04S:
C. 49.20; H, 4.13; N, 3.19; S, 7.30. Found: C, 49.1 l; H, 4.09; N, 3.14; S, 7.19.
Example 58 OMe F O~ ,~O
F ~ S,N
H
F ~ F
F
4-Methoxy-3-nitro-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to example 46 by replacing 3-chloroaniline with 4-methoxy-3-nitroaniline which was prepared by the method of Norris (Aunt. J. Chem. 1971, 2~t, 1449).
Orange-yellow solid, mp 95-97 °C. ~H NMR (CDC13): d 7.64 (d, J= 2.7;
1H), 7.~1 (dd, J=
2.7, 9.0; 1H), 7.09 (s. 1H), 7.09 (d, J= 9.0: 1H), 3.95 (s, 3H). Anal. Calcd.
For C13H7FSN205S: C. 39.21: H, 1.77; N, 7.03; S, 8.0~. Found: C. 39.19; H, 1.73;
N. 6.97; S, 7.95.
SUBSTITUTE SHEET (RULE 26) 1pe59 F ~ OMe F ~ Sp I
H
F ~ F
F
3-Amino-4-methoxy-I-pentafluorophenylsulfonamidobenzene. To a solution of 4-methoxy-3-vitro-1-pentafluorophenylsulfonamidobenzene (627 mg, 1.58 mmol) in ethanol ( 10 mL) was added 10% Pd/C (51 mg). The resulting mixture was stirred under an atmosphere of hydrogen gas at 1 atm pressure. After 14 h, the mixture was passed through a pad of celite and the filtrate was concentrated to give a solid residue.
Silica gel chromatography (2:1, I:1/hexanes:EtOAc) yielded 542 mg (93%) of product as a white solid, mp 142-143 °C. 1 H NMR (DMSO-d6): 10.64 (s, I ), 6.68 (d, J = 8.4; 1 H), 6.44 (d, J = 2.1;
1H), 6.30 (d, J= 2.1, 8.4; 1H), 4.88 (bs, 2H), 3.69 (s, 3H). Anal. Calcd. for C13H9FSN203S:
C, 42.40; H. 2.46; N, 7.61; S, 8.71. Found: C, 42.29; H. 2.36; N, 7.52; S, 8.60.
SUBSTITUTE SHEET (RULE 26) WO 98/05315 PCTlUS97112720 S
F
Exam In a 60 4-Butoxy-I-pentafluorophenylsulfonamidobenzene. To a solution of pentafluorophenylsulfonyl chloride (203 mg, 0.763 mmol) in MeOH (4 mL) was added 4-butoxyaniline (0.26 mL, 1.53 mmol). Afrer stirring at rt for 1 h, the reaction mixture was poured onto 1 M HCl ( 1 ~ mL) and extracted with CH,,CI,, (3 x I 0 mL). The combined organic extracts were washed with saturated NaCI ( 10 mL) and dried (MgS04).
Concentration followed by flash chromatography (25:25:1/hexanes: CH,,CI2:EtOAc) provided 189 mg (63%) of product. 1H NMR (CDC13): d 7.07 (m, 2H), 6.86 (s, IH), 6.80 (m, 2H), 3.89 (t, J= 6.5;
2H), 1.73 (m, 2H), 1.46 (m. 2H), 0.95 (t, J= 7.5; 2H). MS (EI): mlz 395 (30, M+), 164 (35), 108 (100). Anal. Calcd. for C16H~4F5NO3S: C. 48.61: H. 3.~7; N, 3.54; S, 8.11.
Found: C, 48.54; H, 3.53; N, 3.50; S, 8.02.
Example 61 O~
F F O\\S
H
F F
F o o ~ I o I ~
..
F ~ S.N W
H
F ~ F
F
1-Pentafluorophenylsulfonamido-4-phenoxybenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with 4-phenoxyaniline. iH NMR (CDC13): 7.36-7.30 (m, 2H), 7.1 S-7.I0 (m, 3H), 6.99 (s, 1H), 6.98-6.90 (m, 4H). MS (EI): mlz 415 (32; M+), 184 (100). 77 (66). Anal. Calcd.
for C~gH~oF5N03S: C. 52.05: H, 2.43: N, 3.27; S, 7.72. Found: C, 51.78; H, 2.45;
N, 3.25; S, SUBSTITUTE SHEET (RULE 26) 7.53.
Example 62 F O
F ~o s p ~
to I
F ~ ~F
F 4-Benzyloxy-1-pentafluor ophenylsulfonamidobenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with 4-benzyloxyaniline.
15 4-Benzyloxyaniline was obtained from the commercially available hydrochloride salt by treatment with aqueous NaOH. 1H NMR (CDC13): 7.38-7.37 (m, 4H), 7.36-7.32 {m, 1H), 7.10-7.08 (m, 2H), 7.91-7.88 (m, 2H), 6.78 (s, 1H), 5.01 (s. 1H). MS (EI): m/z 429 (19, M+), 91 (100). Anal. Calcd. for C~9H~.,F5N03S: C, 53.14; H, 2.82; N. 3.26: S. 7.45.
Found: C, 53.07; H, 2.78; N, 3.21; S, 7.35.
SUBSTITUTE SHEET (RULE 26) Example 63 F O~ i0 F ~ S. I
I , F ~ ~F
F
4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with 4-(methylmercapto)aniline. 1H NMR (CDC13): 7.17 (m, 2H), 7.09 (m, 2H), 6.89 (m, 1H), 2.44 (s, 3H}. MS (EI): m/z 369 {24, M+), 138 (100), 77 (66). Anal. Calcd. for C~3HgF5NO.,S2: C, 42.28; H, 2.18; N, 3.79; S, 17.36. Found: C. 42.20; H. 2.21;
N. 3.72; S, 17.28.
1 S Example 64 F F O.S
N
I i H CHs F ~ ~F
F
2-Methoxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with o-anisidine.
1H NMR (CDCl3): d 7.54 (dd, J= 1.5, 8.0; 1H), 7.13 (dt, J= 1.5, 8.0; 1H), 6.94 (dt, J= 1.2, 8.0; 1H), 6.84 (dd, J= 1.2. 8.0; 1H), 3.79 (s, 3H). MS (EI): mlz 353 (82, M+), 122 (100}, 94 (95). Anal. Calcd. for C~3H8FSN03S: C, 44.19; H, 2.28; N. 3.97: S, 9.06.
Found: C, 44.10;
H, 2.26; N, 3.92; S, 9.03.
SUBSTITUTE SHEET (RULE 26j WO 98/05315 PCT/US97l12720 Example 65 F \ O
F \O~S~ I /
H
F ~ F
F
4-Allyloxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with 4-allyloxyaniline. 4-Allyloxyaniline was prepared by the method of Butera (J.
Med. Chem.
1991, 3.~. 3212). 'H NMR (CDCl3): 7.08 (m, 2H), 6.87 (m. 1H), 6.82 (m, 2H), 6.04-5.94 (m, 1H), 5.39-5.34 {m, 1H), 5.29-5.25 (m. 1H), 4.48-4.46 (m, 2H). MS (EI): m/z 379 (11. M+).
148 (32). 41 {100). Anal. Calcd. for CISH~oF5NO3S: C, 47.50; H, 2.66; N, 3.96;
S. 8.45.
Found: C, 47.53; H, 2.68; N, 3.62; S. 8.37.
Example 66 O~
F F O~S O I /
I , F ~ ~F
F
1-Pentafluorophenylsulfonamido-4-propoxybenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with 4-propoxyaniline. 4-Propoxyaniline was obtained by catalytic hydrogenation of 4-allyloxynitrobenzene. 4-Allyloxynitrobenzene was prepared by the method of Butera (J.
Med. Chem. 1991. 3~, 3212). 1H NMR (CDCl3): 7.09 (m, 2H), 6.82 (m, 2H), 6.78 (m, 1H), 3.87 (t, J= 6.5; 2H), 1.78 (m, 2H), 1.02 (t, J= 7.4; 3H). MS (EI): mlz 381 (20, M-), 150 (40), 108 (100). Anal. Calcd. for C15Ht2FsN~3S: C, 47.25; H, 3.17; N, 3.67; S, 8.41.
Found: C, 47.01; H, 3.20; N, 3.61; S, 8.31.
SUBSTITUTE SHEET (RULE 26) Example 67 O
F ~~ rr I
F ~ S.N /
H
F / F
F
4-(1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene. The compound was prepared in a manner similar to that described in example 60 by replacing 4-butoxyaniline with 4-isopropoxyaniline. 4-Isopropoxyaniline was prepared from 4-fluoronitrobenzene in analogy to the method of Day (J Med. Chem. 1975. 18, 1065). jH NMR (CDC13): 7.08 (m, 2H), 7.00 (s, 1H), 6.81 (m, 2H), 4.48 (heptet, J= 6.1: 1H), 1.30 (d, J= 6.04; 6H).
MS (EI): mlz 381 (7, Mt), 339 (8}, 108 (100). Anal. Calcd. for C15H1,,FSN03S: C, 47.25; H, 3.17; N, 3.67; S, 8.41. Found: C, 47.08; H. 3.18; N, 3.60; S, 8.34.
1 S Example 68 F F ~S~ ~
O
2o F ~ F
F
1-Pentafluorophenylsulfonyloxybenzene. To a stirred solution of phenol (0.068g, 0.729mmo1) in dimethylformamide (3.65 mL) at 25 °C is added pentafluorophenyl sulfonyl chloride (0.135mL, 0.911mmo1), followed by sodium carbonate (0.116g, 1.09mmol), and the 25 reaction mixture is stirred for 18 hours. The reaction mixture is diluted with ethyl acetate (SOmL), washed with 20% ammonium chloride (2 x 20mL}, and saturated sodium chloride (2 x 20mL). The organic layer is dried (sodium sulfite), and the ethyl acetate removed under vacuum. Column chromatography (3/1 ethyl acetate/hexane) yields the title compound.
SUBSTITUTE SHEET (RULE 26) F F oso ~N
F ~ ~F
F
1-Pentafluorophenyisulfonylindole. To a stirred solution of indole (0.085g, 0.729mmol) in dimethylformamide (3.6~ mL) at 25 ~C is added pentafluorophenyl sulfonyl chloride (0.135mL, 0.911mmol), followed by sodium carbonate (0.116g, 1.09mmo1), and the reaction mixture is stirred for 18 hours. The reaction mixture is diluted with ethyl acetate (SOmL), washed with 20% ammonium chloride (2 x 20mL), and saturated sodium chloride (2 x 20mL).
The organic layer is dried (sodium sulfite), and the ethyl acetate removed under vacuum.
Column chromatography (3/1 ethyl acetate/hexane) yields the title compound.
Exam 112 a 70 F O / OMe F S\ ~
/ N F
F ~ F H
F
2-Fluoro-1-methoxy-4-pentafluorophenylsulfinamidobenzene. To 3-fluoro-p-anisidine (3g, 21.2mmo1) suspended in THF (SOmL) with pyridine ( 1.84g, 23.3mmol) at 0 °C under argon is added dropwise pentafluorophenylsulfinyl chloride (5.3g, 21.2mmol). The reaction mixture is stirred for 30 min. at 0 °C and allowed to warm to ambient temperature.
The reaction mixture is strirred at room temperature and followed by TLC. After the reaction is completed the mixture is diluted with ethyl acetate and the reaction quenched with water.
The layers are separated and the aqueous layer extracted twice with ethyl acetate. The organic layers are combined and dried with brine and with Na.,S04. The solvent is evaporated and the residue purified by chromatography on silica to give the title compound.
SUBSTITUTE SHEET (RULE 26) Example 71 F
F ~ S.N ~N
H HN
F F
F
2-Anilino-3-pentafluorophenylsulfonamidopyridine. To a solution of 10 pentafluorophenylsulfonyl chloride (863 mg, 3.24 mmol) in pyridine (9 mL) at rt was added 3-amino-2-analinopyridine (600 mg, 3.24 mmol). After stirring at rt overnight the reaction mixture was concentrated at reduced pressure and the residue partitioned between 1 M Hcl (50 mL) and CH2C12 (50 mL). The organic extract was dried and concentrated to give an oil which was purified by MPLC to give 377 mg (28%) of product as an orange solid.
H~ NMR
15 (CDC13): 8.50 (bs, 1 H), 7.80 (d, J=5.1, 1 H), 7.61 (d, J=8.0, 1 H), 7.32 (t, J=8.0, 2H), 7.25 (d, J=8.0, 2H), 7.11 (t, J=7.3, 1 H), 6.80 (dd, J=5.6, 7.7, 1 H), 4.20 (bs, 1 H).
MS (FAB): mlz 438 (M+Na), 416 (M+H).
Example 72 20 4-[3H)-1-Fluoro-2-methoxy-~-pentafluorosulfonamidobenzene.
A solution of 1-bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene {27.8 mg, 0.058 mmol; prepared in Example 41) in ethyl acetate (2 mL) was treated with 100 mg of 10% palladium on charcoal. The air in the reaction vessel was evacuated and replaced with tritium gas. After 2 h of stirnng at room temperature, the catalyst was filtered, the solvent 25 was evaporated, and the crude product purified by preparative thin layer chromatography (TLC) using dichloromethane as the eluent. The sample purity was characterized by HPLC
using a Microsorb silica (250x4.6mm) 5 mm column and 15% ethyl acetate/hexane as the mobile phase. The elution of material was detected using a UV detector at 254 nm and a Beta Ram detector. The chemical purity of this material was determined to be 100%, and the 30 radiochemical purity was 99.3%. The specific activity of this material was Ci/mmol.
SUBSTITUTE SHEET (RULE 26) Compounds were evaluated for their ability to inhibit in vitro the growth of HeLa cells, an immortal cell line derived from a human cervical carcinoma commonly used to evaluate the cytotoxicity of potential therapeutic agents. The following data reflect the cytotoxicity of selected examples of the present invention. The values given represent the concentration of test compound required to inhibit by SO% the uptake of Alamar Blue (Biosource International, Camarillo, CA) by HeLa cell cultures, which correlates directly with the overall levels of cellular metabolism in the culture, and is generally accepted as an appropriate marker of cell growth. The test was conducted according to the method flf S:A. Ahmed et al. (1994) J. Immunol. Methods 170: 211-224. The following selected examples display potent cytotoxic activity in this assay, with ICSO values ranging from less than 0.05 ~1M to 10 ltM.
o a d ICSOIuMI

Example 1 < 0.05 Example 2 ~ ' 0.15 Example 3 1.5 Example 4 I 0 Example 6 < 0.05 Example 7 < 0.05 Example 8 < 0.05 Example 9 1 Example 12 0.15 Example 15 1 Example 17 10 Example 25 10 Example 30 I.5 Example 31 0.5 Example 32 0.1 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims (37)

WHAT IS CLAIMED IS
1. The use of a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat or prevent a disease state characterized by an abnormal or undesired level of cell proliferation:

wherein: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R1 is selected from hydrogen, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and R2 is substituted or unsubstituted aryl.
2. The use of a compound of formula I, or a pharmaceutically acceptable salt thereof, to formulate a medicament to treat or prevent a disease state characterized by an abnormal or undesired level of cell proliferation:

wherein: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R1 is selected from hydrogen, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and R2 is substituted or unsubstituted aryl.
3. The use of the compound according to claim 1 or 2, wherein R1 is hydrogen or lower alkyl, and R2 is optionally substituted phenyl.
4. The use of the compound according to claim 3, wherein R1 is hydrogen or methyl, and the substituents on R2 are independently selected from lower alkyl, hydroxy, lower alkoxy, amino, amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen.
5. The use of the compound according to claim 4, wherein the compound is selected from the group consisting of:

4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Diethylamino)-1-pentafluorophenylsulfonamidobenzene, 4-Amino-1-pentafluorophenylsulfonamidobenzene, Pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-(N,N-Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene, 1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Phenoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4(1-Morpholino)-1-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene, 2-Hydroxy-1,3-dimethoxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene, 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene hydrochloride, 3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene, 4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-[N-(5-hydroxypentyl)pentafluorophenylsulfonamido]-benzene, 4-(1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-s-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenyisulfonamidobenzene; potassium salt, 3-Chloro-1-pentafluorophenylsulfonamidobenzene, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, 3-Nitro-1-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamido-3-trifluoromethylbenzene, 4-Methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)benzene, 4-Methoxy-3-nitro-1-pentafluorophenylsulfonamidobenzene, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Butoxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-phenoxybenzene, 4-Benzyloxy-1-pentafluorophenylsulfonamidobenzene, 4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene, 2-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Allyloxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-propoxybenzene, 4-(1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, and 4-tert-Butoxy-1-pentafluorophenylsulfonamidobenzene.
6. The use of the compound according to claim 5, wherein the compound is selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorosulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, and 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
7. The use of the compound according to claim 6, wherein the compound is selected from the group consisting of 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, and 2-Hydroxy-1-methoxy-pentafluorophenylsulfonamidobenzene; monopotassium salt.
8. The use of the compound according to claim 6, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene.
9. The use of the compound according to claim 6, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt.
10. The use of the compound according to claim 6, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt.
11. The use of the compound according to any one of claims 1 through 10 in which the compound of formula I is used to contact a target cell to inhibit the growth of the target cell.
12. The use of the compound according to any one of claims 1 through 10, wherein the proliferative disease state is cancer or a cancerous condition.
13. The use of the compound according to any one of claims 1 through 10, wherein the compound is formulated for oral administration.
14. The use of the compound according to any one of claims 1 through 10, wherein the compound is formulated for intravenous administration.
15. The use of the compound according to any one of claims 1 through 10, wherein the compound is formulated for intramuscular administration.
16. The use of the compound according to any one of claims 1 through 15, in combination with the use of an antineoproliferative, chemotherapeutic, or cytotoxic agent that is not represented by formula I.
17. The use of the compound according to any one of claims 1 through 16, wherein the compound is conjugated to a targeting molecule which preferentially directs the compound to a targeted cell.
18. The use of the compound according to any one of claims 1, 2, 11, 12, 13, 14, 15, 16 or 17, wherein R1 is hydrogen or methyl, and R2 is substituted phenyl wherein the substituents on R2, ranging in number from one to four are independently chosen from lower alkyl, lower alkoxy, amino optionally substituted with one or two lower alkyls, arylamino, heteroarylamino, phenoxy, and halogen.
19. A method of inhibiting the growth of a target cell in vitro, comprising contacting said cell with an effective amount of a compound of formula I, or a salt thereof wherein: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R1 is selected from hydrogen, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and R2 is substituted or unsubstituted aryl.
20. A method for the preparation of a pharmaceutical composition for the treatment of a disease state characterized by an abnormal or undesired level of cell proliferation comprising formulating a pharmaceutically acceptable diluent or carrier with a compound of formula I, or a pharmaceutically acceptable salt thereof:
wherein: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R1 is selected from hydrogen, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and R2 is substituted or unsubstituted aryl.
21. The method of claim 19 or 20, wherein R1 is hydrogen or lower alkyl, and R2 is optionally substituted phenyl.
22. The method of claim 21, wherein R1 is hydrogen or methyl, and the substituents on R2 are independently selected from lower alkyl, hydroxy, lower alkoxy, amino; amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen.
23. The method of claim 22, wherein the compound is selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Diethylamino)-1-pentafluorophenylsulfonamidobenzene, 4-Amino-1-pentafluorophenylsulfonamidobenzene, Pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-(N,N-Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene, 1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Ethoxy-1-pentafluorophenylsulfonamidobenzene, so 3-Phenoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4(1-Morpholino)-1-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene, 2-Hydroxy-1,3-dimethoxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene, 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene hydrochloride, 3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene, 4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-[N-(5-hydroxypentyl)pentafluorophenylsulfonamido]-benzene, 4-(1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenyisulfonamidobenzene; potassium salt, 3-Chloro-1-pentafluorophenylsulfonamidobenzene, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, 3-Nitro-1-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamido-3-trifluoromethylbenzene, 4-Methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluoxophenylsulfonamido)benzene, 4-Methoxy-3-nitro-1-pentafluorophenylsulfonamidobenzene, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Butoxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-phenoxybenzene, 4-Benzyloxy-1-pentafluorophenylsulfonamidobenzene, 4-Methylmercapto-1-pentafluorophenylsulfonamidobenzene, 2-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Allyloxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-propoxybenzene, 4-(1-Methyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, and 4-tert-Butoxy-1-pentafluorophenylsulfonamidobenzene.
24. The method of claim 23, wherein the compound is selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorosulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, and 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
25. The method of claim 24, wherein the compound is selected from the group consisting of 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, and Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt.
26. The method of claim 24, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene.
27. The method of claim 24, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt.
28. The method of claim 24, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt.
29. A commercial package containing, as active pharmaceutical ingredient, a compound of formula I, or a pharmaceutically acceptable salt thereof, together with instructions for use of the compound for the treatment or prevention of a disease state characterized by an abnormal or undesired level of cell proliferation:

wherein: Y is -S(O)- or -S(O)2-; Z is -NR1R2; where R1 is selected from hydrogen, substituted or unsubstituted (C1-C10)alkyl, substituted or unsubstituted (C3-C6)alkenyl and substituted or unsubstituted (C2-C6)heteroalkyl, and R2 is substituted or unsubstituted aryl.
30. The commercial package of claim 29, wherein R1 is hydrogen or lower alkyl, and R2 is optionally substituted phenyl.
31. The commercial package of claim 30, wherein R1 is hydrogen or methyl, and the substituents on R2 are independently selected from lower alkyl, hydroxy, lower alkoxy, amino, amino optionally substituted with one or two lower alkyls, optionally substituted arylamino, optionally substituted heteroarylamino, optionally substituted phenoxy, and halogen.
32. The commercial package of claim 31, wherein the compound is selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 4-Hydroxy-1-pentafluorophenylsulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Diethylamino)-1-pentafluorophenylsulfonamidobenzene, 4-Amino-1-pentafluorophenylsulfonamidobenzene, Pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethyl amino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-(N,N-Dimethylamino)-1-(pentafluorophenylsulfonamido)benzene, 1,2-Dihydroxy-4-pentafluorophenylsulfonamidobenzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3,5-Dimethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Phenoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4(1-Morpholino)-1-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trimethoxybenzene, 2-Hydroxy-1,3-dimethoxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 5-Pentafluorophenylsulfonamido-1,2,3-trihydroxybenzene, 1,3-Dimethoxy-2-hydroxy-5-pentafluorophenylsulfonamidobenzene, 1,2-Dihydroxy-3-methoxy-5-pentafluorophenylsulfonamidobenzene, 3-Hydroxy-5-methoxy-1-pentafluorophenylsulfonamidobenzene;
3,5-Dihydroxy-1-pentafluorophenylsulfonamidobenzene, 2-Fluoro-1-methoxy-4-(N-methylpentafluorophenylsulfonamido)benzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene hydrochloride, 3,4-Difluoro-1-pentafluorophenylsulfonamidobenzene, 4-Trifluoromethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-[N-(5-hydroxypentyl)pentafluorophenylsulfonamido]-benzene, 4-(1,1-Dimethyl)ethoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Hydroxy-1-methoxy-4-pentafluoraphenylsulfonamidobenzene; potassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 3-Chloro-1-pentafluarophenylsulfonamidobenzene, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, 3-Nitro-1-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluaraphenylsulfonamido-3-trifluoromethylbenzene, 4-Methoxy-1-(N-(2-propenyl)pentafluorophenylsulfonamido)benzene, 1-(N-(3-Butenyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(4-pentenyl)pentafluorophenylsulfonamido}benzene, 1-(N-(2,3-Dihydroxypropyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(3,4-Dihydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 1-(N-(4,5-Dihydroxypentyl)pentafluorophenylsulfonamido}-4-methoxybenzene, 1-(N-(4-hydroxybutyl)pentafluorophenylsulfonamido)-4-methoxybenzene, 4-Methoxy-1-(N-(5-hydroxypentyl)pentafluorophenylsulfonamido)benzene, 4-Methoxy-3-nitro-1-pentafluaraphenylsulfonamidobenzene, 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Butoxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-phenaxybenzene, 4-Benzyloxy-1-pentafluorophenylsulfonamidobenzene, 4-Methylmercapto-1-pentafluorophenyl sulfonamidobenzene, 2-Methoxy-1-pentafluorophenylsulfonamidobenzene, 4-Allyloxy-1-pentafluorophenylsulfonamidobenzene, 1-Pentafluorophenylsulfonamido-4-propoxybenzene, 4-(1-Methyl)ethoxy-l-pentafluorophenylsulfonamidobenzene, and 4-tert-Butoxy-1-pentafluorophenylsulfonamidobenzene.
33. The commercial package of claim 32, wherein the compound is selected from the group consisting of:
4-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 3-(N,N-Dimethylamino)-1-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfanamidobenzene, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 4-Methoxy-1-pentafluorophenylsulfonamidobenzene, 3 -Hydroxy-1-pentafluorophenylsulfonamidobenzene;
4-Hydroxy-1-pentafluorosulfonamidobenzene, 1,2-Dimethyl-4-pentafluorophenylsulfonamidobenzene, 4-(N,N-Dimethylamino)-1-(N-methylpentafluorophenylsulfonamido)benzene, 4-Ethoxy-1-pentafluorophenylsulfonamidobenzene, 3-Methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Chloro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Bromo-3-hydroxy-4-methoxy-1-pentafluorophenylsulfonamidobenzene, 2-Bromo-4-methoxy-5-hydroxy-1-pentafluorophenylsulfonamidobenzene, 1-Bromo-4-fluoro-5-methoxy-2-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monopotassium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; sodium salt, 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene; potassium salt, 4-Chloro-1-pentafluorophenylsulfonamidobenzene, and 3-Amino-4-methoxy-1-pentafluorophenylsulfonamidobenzene.
34. The commercial package of claim 33, wherein the compound is selected from the group consisting of 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene, 2-Hydroxy-1-methoxy-4-pentafluorophenylsulfonamidobenzene; monosodium salt, and 2-Hydroxy-1-methoxy-pentafluorophenylsulfonamidobenzene; monopotassium salt.
35. The commercial package of claim 33, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene.
36. The commercial package of claim 33, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, sodium salt.
37. The commercial package of claim 33, wherein the compound is 2-Fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene, potassium salt.
CA002260777A 1996-07-19 1997-07-18 Pentafluorobenzenesulfonamides and analogs Expired - Fee Related CA2260777C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2219896P 1996-07-19 1996-07-19
US60/022,198 1996-07-19
PCT/US1997/012720 WO1998005315A1 (en) 1996-07-19 1997-07-18 Pentafluorobenzenesulfonamides and analogs

Publications (2)

Publication Number Publication Date
CA2260777A1 CA2260777A1 (en) 1998-02-12
CA2260777C true CA2260777C (en) 2006-06-13

Family

ID=21808333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260777A Expired - Fee Related CA2260777C (en) 1996-07-19 1997-07-18 Pentafluorobenzenesulfonamides and analogs

Country Status (15)

Country Link
US (2) US6482860B1 (en)
EP (1) EP0939627B1 (en)
JP (1) JP3421350B2 (en)
CN (1) CN1147294C (en)
AT (1) ATE249214T1 (en)
AU (1) AU710173B2 (en)
BR (1) BR9710737A (en)
CA (1) CA2260777C (en)
DE (1) DE69724811T2 (en)
DK (1) DK0939627T3 (en)
ES (1) ES2201313T3 (en)
HK (1) HK1021699A1 (en)
IL (2) IL127965A0 (en)
PT (1) PT939627E (en)
WO (1) WO1998005315A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896533B1 (en) * 1996-02-22 2003-09-10 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
JP3421350B2 (en) * 1996-07-19 2003-06-30 テュラリク インコーポレイテッド Pentafluorobenzenesulfonamide and analogs
JP2002518506A (en) 1998-06-25 2002-06-25 テュラリク インコーポレイテッド Aryl sulfone anilide phosphate
US6153585A (en) 1998-07-20 2000-11-28 Tularik Inc. Arylsulfonanilide derivatives
SK284757B6 (en) * 1998-09-23 2005-11-03 Tularik Inc. Arylsulfonanilide ureas, pharmaceutical composition containing them and use thereof
EP1285911A3 (en) * 1998-09-23 2003-03-26 Tularik Inc. Arylsulfonanilide ureas
AU731777B2 (en) * 1998-11-30 2001-04-05 Nihon Nohyaku Co., Ltd. Aniline derivative and process for producing the same
WO2000035865A2 (en) * 1998-12-17 2000-06-22 Tularik Inc. Tubulin-binding agents
JP2001026506A (en) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd Sulfonamide derivative
US6521658B1 (en) 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
CO5170498A1 (en) * 1999-05-28 2002-06-27 Abbott Lab BIARIL SULFONAMIDS ARE USEFUL AS CELL PROLIFERATION INHIBITORS
WO2001008693A2 (en) * 1999-07-29 2001-02-08 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU1806800A (en) * 1999-08-17 2001-03-13 Tularik Inc. Arylsulfonanilide derivatives
US6306615B1 (en) 1999-08-19 2001-10-23 Tularik Inc. Detection method for monitoring β tubulin isotype specific modification
US6432427B1 (en) 2000-06-30 2002-08-13 Unilever Hope & Personal Care Usa, Division Of Conopco, Inc. Cosmetic compositions containing substituted sulfonamide derivatives
AU9619301A (en) * 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US6822001B2 (en) 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
FR2836914B1 (en) * 2002-03-11 2008-03-14 Aventis Pharma Sa SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
US6946466B2 (en) 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
EA200501607A1 (en) * 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи REPLACED PHYLALICANE ACIDS
WO2005007621A2 (en) * 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
AU2005302475A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids
DE102006016258A1 (en) * 2005-05-14 2007-02-15 Universität Stuttgart New non, partially or perfluorinated aromatic, monomeric, oligomeric, polymeric sulfone- and/or phosphonic acids, produced by nucleophilic aromatic substitution with sulfur and/or phosphorous nucleophile, useful e.g. in membrane procedure
GB0526445D0 (en) * 2005-12-23 2006-02-08 Novartis Ag Organic compounds
KR100932093B1 (en) 2006-09-27 2009-12-16 주식회사종근당 Benzophenone Derivatives Useful as Inhibitors of Microtubule Formation
JP2013532688A (en) * 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Sulfonamide compounds useful as CYP17 inhibitors
CN104447536B (en) * 2014-10-25 2017-04-12 大连理工大学 Preparation method of N-2-quinolyl aryl sulfonamide compounds
US20200277268A1 (en) * 2017-09-21 2020-09-03 Dalriada Therapeutics Inc. Pentafluorophenyl sulfonamide compounds, compositions and uses thereof
US11555012B2 (en) * 2018-11-09 2023-01-17 Nimbus Artemis, Inc. ACLY inhibitors and uses thereof
US20220169598A1 (en) * 2019-03-27 2022-06-02 2681603 Ontario Inc. Halogenated phenylsulfonamide hydroxamic acid compounds, compositions and uses thereof as selective hdac6 inhibitors
EP4017843A4 (en) * 2019-07-17 2023-07-26 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
KR20230147036A (en) * 2020-11-20 2023-10-20 2692372 온타리오 인크. Benzenesulfonamide derivatives and uses thereof
WO2022106897A2 (en) * 2020-11-20 2022-05-27 2692372 Ontario, Inc. Methods and composition for kras modifications

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1955207A (en) 1931-09-16 1934-04-17 Ig Farbenindustrie Ag Mothproofing agent
US2402623A (en) 1943-06-24 1946-06-25 Rohm & Haas Nu-nitroaryl haloarylsulphonamides
CH362688A (en) * 1957-09-10 1962-06-30 Geigy Ag J R Process for the preparation of new arylsulfonarylamides
GB1242057A (en) 1968-07-04 1971-08-11 Ici Ltd Derivatives of 4-hydroxytetrafluoropyridine and the use thereof as plant growth regulators
NL174644C (en) 1970-04-13 1984-07-16 Minnesota Mining & Mfg METHOD FOR PREPARING A HERBICIDE COMPOUND; ALSO METHOD FOR PREPARING A PREPARATION WITH HERBICIDE ACTION.
DE3000377A1 (en) * 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim NEW SULPHONAMIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3623184A1 (en) 1986-07-10 1988-01-14 Kali Chemie Ag METHOD FOR PRODUCING N-FLUORSULFONAMIDES
DE3632329A1 (en) * 1986-09-24 1988-03-31 Bayer Ag SUBSTITUTED PHENYLSULPHONAMID
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
DE3804990A1 (en) 1988-02-18 1989-08-31 Basf Ag HERBICIDALLY EFFECTIVE, HETEROCYCLICALLY SUBSTITUTED SULFONAMIDES
FR2645537B1 (en) 1989-04-05 1994-03-04 Fabre Medicament Pierre NOVEL SULFONAMIDES DERIVED FROM BENZOCYCLIC OR BENZOHETEROCYCLIC ACIDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2665440B1 (en) 1990-07-31 1994-02-04 Lipha NOVEL SUBSTITUTED CYCLOALKYLSULFONAMIDES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
US5189211A (en) 1990-08-01 1993-02-23 Taisho Pharmaceutical Co., Ltd. Sulfonamide derivatives
ATE167473T1 (en) * 1990-08-20 1998-07-15 Eisai Co Ltd SULFONAMIDE DERIVATIVES
CH681529A5 (en) 1990-08-21 1993-04-15 Alusuisse Lonza Services Ag
DE19581653T1 (en) * 1994-05-25 1997-07-17 Dow Chemical Co Sulfonamides, usable as lubricants in magnetic recording media
AU6112896A (en) * 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
EP0896533B1 (en) 1996-02-22 2003-09-10 Tularik, Inc. Pentafluorobenzenesulfonamides and analogs
JP3421350B2 (en) * 1996-07-19 2003-06-30 テュラリク インコーポレイテッド Pentafluorobenzenesulfonamide and analogs
US5773236A (en) * 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
US6284923B1 (en) * 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
AU1208999A (en) 1997-11-10 1999-05-31 Array Biopharma, Inc. Compounds which inhibit tryptase activity
US6153585A (en) * 1998-07-20 2000-11-28 Tularik Inc. Arylsulfonanilide derivatives
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
WO2001008693A2 (en) * 1999-07-29 2001-02-08 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents

Also Published As

Publication number Publication date
JP2000515545A (en) 2000-11-21
EP0939627B1 (en) 2003-09-10
ATE249214T1 (en) 2003-09-15
EP0939627A4 (en) 2000-10-04
ES2201313T3 (en) 2004-03-16
DK0939627T3 (en) 2003-10-13
DE69724811T2 (en) 2004-04-08
DE69724811D1 (en) 2003-10-16
IL127965A0 (en) 1999-11-30
US20030162817A1 (en) 2003-08-28
CN1147294C (en) 2004-04-28
US6482860B1 (en) 2002-11-19
PT939627E (en) 2004-02-27
EP0939627A1 (en) 1999-09-08
US6962929B2 (en) 2005-11-08
CA2260777A1 (en) 1998-02-12
AU3887797A (en) 1998-02-25
HK1021699A1 (en) 2000-06-30
IL127965A (en) 2006-08-20
AU710173B2 (en) 1999-09-16
CN1225009A (en) 1999-08-04
WO1998005315A1 (en) 1998-02-12
JP3421350B2 (en) 2003-06-30
BR9710737A (en) 2000-01-11

Similar Documents

Publication Publication Date Title
CA2260777C (en) Pentafluorobenzenesulfonamides and analogs
CA2244785C (en) Pentafluorobenzenesulfonamides and analogs
JP5506386B2 (en) P53 activating compound
US9663482B2 (en) Substituted piperazinyl acetohydrazide procaspase-activating compounds
JP2001514167A (en) Substituted benzene compounds as cytostatics and cholesterol lowering agents
KR100671243B1 (en) Pentafluorobenzenesulfonamides and analogs
Facchinetti et al. Evaluation of (2 S, 3 R)-2-(amino)-[4-(N-benzylarenesulfonamido)-3-hydroxy-1-phenylbutane derivatives: a promising class of anticancer agents
Soni DEVELOPMENT OF SALINOMYCIN DERIVATIVES AS POTENTIAL ANTICANCER AGENTS
JP6654771B2 (en) Compounds that are 4-oxo-n- (4-hydroxyphenyl) retinamide derivatives or pharmaceutically acceptable salts thereof as therapeutic agents for treating cancer, combination medicaments using them, and pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed